The CEA Registry Blog

By CEA Registry Team on 3/27/2014 10:26 AM

By Teja Thorat, M.Sc., M.P.H, Peter Neumann, Sc.D., and Joshua T. Cohen, Ph.D.

When we recently updated the CEA Registry for 2012, it became apparent that there was a notable spike in the number of studies added that year. Roughly 45 percent more cost-utility analyses (CUAs) were published in PubMed in 2012 than 2011 (538 versus 372).



We have identified two potential explanations for the increase:

•    Journals that have published CUAs in the past, such as the Journal of Medical Economics, PLoS ONE, Clinical Therapeutics, Pharmacoeconomics, BMJ Open, International Journal of Technology Assessment in Health Care have increased the number of CUAs they are publishing. Between 2011 and 2012, these journals have more than doubled the number of CUAs they published.

•    There was a rise in the number of journals publishing CUAs for the first time in 2012, reflecting a growing interest in the field. The Registry included 60 journals that were first-time publishers of CUAs during 2012, such as Acta Ophthalmologica, Bulletin of the World Health Organization, Journal of the American Medical Informatics Association, Journal of Cancer, Clinical Rheumatology. These include existing journals that have started publishing CUAs, or brand-new journals, or journals newly indexed on PubMed. 

Journals

Number of CUAs

2012

2011

Change from previous year

Journal of Medical Economics

38

11

27

PLoS One

21

11

10

Clinical Therapeutics

15

7

8

Pharmacoeconomics

14

7

7

BMJ Open

8

2

6

International Journal of Technology Assessment in Health Care

9

4

5

Osteoporosis International

6

1

5

Heart

6

1

5

Applied Health Economics and Health Policy

7

3

4

BMC Health Services Research

7

3

4

Breast Cancer Research and Treatment

5

1

4

European Heart Journal

4

0

4

AIDS and Behavior

4

0

4

 

Our initial count of articles published in 2013 suggests that the number of CUAs published in 2013 will be comparable to the number published in 2012. As seen in recent years, we can also expect more CUAs from emerging market countries, such as China, Japan and South Korea. For example, the number of CUAs from China increased from 3 in 2011 to 10 in 2012.  

Although we still do not understand why there has been a dramatic increase in the publication of CUAs, it is possible that it reflects an increased interest in assessing economic value, a sense that cost-utility analysis is an effective way to address this issue and to communicate findings, or some combination of the two.

 

By CEA Registry Team on 2/27/2014 9:43 AM

By Cayla Saret, BA

In a commentary published online recently in Genetics in Medicine, Scott Grosse, a health economist at the CDC’s National Center on Birth Defects and Developmental Disabilities, suggests that researchers wait to conduct cost-utility analyses (CUAs) of personalized medicine tests until evidence of their clinical utility is more thoroughly validated.(1)

Grosse worries that in the relatively new field of personalized medicine tests, cost-effectiveness studies based on early evaluations of their clinical utility may later prove unreliable.

His comments come in response to the first review, also appearing in Genetics in Medicine, to evaluate the economic value of personalized medicine tests. This research, led by Kathryn Phillips of the University of San Francisco, examined 59 CUAs published between 1998 and 2011.(2) These studies were included in the Tufts Medical Center Cost-Effectiveness Analysis Registry, a database of CUAs of health interventions.

The analysis suggests that many personalized medicine tests are relatively cost-effective. It also found that 20 percent of genetic tests saved money. However, as Grosse points out, Phillips and colleagues were careful not to draw conclusions about the cost effectiveness of genetic tests in personalized medicine as a whole.

Grosse cautions against making generalizations about the cost effectiveness of genetic tests before there is strong medical evidence of their effectiveness in improving patient outcomes. For example, he is concerned that a CUA might help decide whether to invest time and resources in a test for a cancer mutation, even though the CUA was carried out using weak evidence about the test’s clinical value. 

Phillips and her research team acknowledged that many genetic tests lack firm evidence of their clinical value. They observe, however, that often by the time this information is available, payers may have already decided whether to adopt or reject the test. So an assessment of benefits, risks, and costs is valuable in part because it occurs early in the process.

“We constantly grapple with the uncertain nature of evidence surrounding these and other new technologies,” says study co-author Peter Neumann, director of the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center. “However, decisions about new technologies, such as personalized medicine testing, need to be made on an ongoing basis.  CUAs can help inform those decisions, though we need to do a better job of understanding and characterizing the uncertainty.”

As Grosse highlights, there is value in waiting for more evidence. But constructing too high a bar for it also has consequences. Ultimately, there is a need to weigh the costs and benefits of acquiring additional information. 


References

    1.     Grosse SD. Economic analyses of genetic tests in personalized medicine: clinical utility first, then cost utility. Genet Med e-pub ahead of print  14 Nov 2013.
    2.     Phillips KA, Sakowski JA, Trosman J, Douglas MP, Liang SY, Neumann P. The economic value of personalized medicine tests: what we know and what we need to know. Genet Med e-pub ahead of print  14 Nov 2013.


 

By CEA Registry Team on 1/3/2012 12:20 PM

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1. Richardson SS, Berven S. The development of a model for translation of the Neck Disability Index to utility scores for cost-utility analysis in cervical disorders. Spine J. 2011 Dec 29. [Epub ahead of print] PubMed PMID: 22209244.

2. Bouvy JC, Koopmanschap MA, Shah RR, et al. The Cost-Effectiveness of Drug Regulation: The Example of Thorough QT/QTc Studies. Clin Pharmacol Ther. 2011 Dec 28. doi: 10.1038/clpt.2011.224. [Epub ahead of print] PubMed PMID: 22205197.

3. Brydak L, Roiz J, Faivre P, et al. Implementing an Influenza Vaccination Programme for Adults Aged ≥65 Years in Poland: A Cost-Effectiveness Analysis. Clin Drug Investig. 2011 Dec 27. [Epub ahead of print] PubMed PMID: 22201294.

4. Montero AJ, Avancha K, Glück S, et al. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer. Breast Cancer Res Treat. 2011 Dec 27. [Epub ahead of print] PubMed PMID: 22200867.

5. Anokye NK, Trueman P, Green C, Pavey TG, Hillsdon M, Taylor RS. The cost-effectiveness of exercise referral schemes. BMC Public Health. 2011 Dec 26;11(1):954. [Epub ahead of print] PubMed PMID: 22200193.

6. Wilson RD, Howe EC. A Cost-Effectiveness Analysis of Screening Methods for Dysphagia After Stroke. PM R. 2011 Dec 23. [Epub ahead of print] PubMed PMID: 22197380.

7. van Gils PF, Over EA, Hamberg-van Reenen HH, et al. The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population. BMJ Open. 2011 Dec 21;1(2):e000363. Print 2011. PubMed PMID: 22189351.

8. Gandjour A. Presenting Germany's drug pricing rule as a cost-per-QALY rule. Health Care Manag Sci. 2011 Dec 21. [Epub ahead of print] PubMed PMID: 22187356.

9. Holmes M, Carroll C, Papaioannou D. Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Hip or Knee Surgery: A NICE Single Technology Appraisal. Pharmacoeconomics. 2011 Dec 20. [Epub ahead of print] PubMed PMID: 22185183.

10. Cuthbertson BH, Campbell MK, Stott SA, et al. A pragmatic multi-centre randomised controlled trial of fluid loading in high-risk surgical patients undergoing major elective surgery - the FOCCUS study. Crit Care. 2011 Dec 16;15(6):R296. [Epub ahead of print] PubMed PMID: 22177541.

11. Naci H, de Lissovoy G, Hollenbeak C, et al. Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents  versus routine blood transfusions: a retrospective cost-effectiveness analysis. J Med Econ. 2011 Dec 16. [Epub ahead of print] PubMed PMID: 22115328.

By James D. Chambers

By CEA Registry Team on 12/16/2011 7:35 PM

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Kim S, Mortaz Hedjri S, Coyte PC, et al. Cost-utility of lumbar decompression with or without fusion for patients with symptomatic degenerative lumbar spondylolisthesis. Spine J. 2011 Dec 9. [Epub ahead of print] PubMed PMID: 22169001.

2: Soini E, Hallinen T, Puolakka K, et al. Cost-effectiveness of adalimumab, etanercept and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. J Med Econ. 2011 Dec 14. [Epub ahead of  print] PubMed PMID: 22168785.

3: Kondo M, Yamagata K, Hoshi SL, Saito C, Asahi K, Moriyama T, Tsuruya K, Yoshida H, Iseki K, Watanabe T. Cost-effectiveness of chronic kidney disease mass screening test in Japan.  Clin Exp Nephrol. 2011 Dec 14. [Epub ahead of print] PubMed PMID: 22167460.

4: Liu S, Schwarzinger M, Carrat F, Goldhaber-Fiebert JD. Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients. PLoS One. 2011;6(12):e26783.  Epub 2011 Dec 2. PubMed PMID: 22164204; PubMed Central PMCID: PMC3229483.

5: Nosyk B, Sharif B, Sun H, Cooper C, Anis AH; on behalf of the CIHR Canadian HIV Trials Network Influenza Vaccine Research Group. The Cost-Effectiveness and Value of Information of Three Influenza Vaccination Dosing Strategies for Individuals with Human  mmunodeficiency Virus. PLoS One. 2011;6(12):e27059. Epub PMID: 22162988

6: Palmer AJ, Tucker DM. Cost and clinical implications of diabetes prevention in an Australian setting: A long-term modeling analysis. Prim Care Diabetes. 2011 Dec 6. [Epub ahead of print] PubMed PMID: 22153888.

7: Townsend R, McEwan P, Kim R, Yuan Y. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value  Health. 2011 Dec;14(8):1068-77. PubMed PMID: 22152176.

8: Hoyle M, Rogers G, Moxham T, Liu Z, Stein K. Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia. Value Health. 2011 Dec;14(8):1057-67. PMID: 22152175.

9: Simpson KN, Baran RW, Kirbach SE, et al. Economics of Switching to Second-Line Antiretroviral Therapy with Lopinavir/Ritonavir in Africa: Estimates  Based on DART Trial Results and Costs for Uganda and Kenya. Value Health. 2011 Dec;14(8):1048-54. PMID: 22152173.

10: Hoogendoorn M, Rutten-van Mölken MP, Hoogenveen RT, et al. Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease. Value Health. 2011 Dec;14(8):1039-47. PMID: 22152172.

11: Fang C, Otero HJ, Greenberg D, et al. Cost-utility analyses of diagnostic laboratory tests: a systematic review. Value Health. 2011 Dec;14(8):1010-8. PMID: 22152169.

12: Park H, Rascati KL, Keith MS, et al. Cost-Effectiveness of Lanthanum Carbonate versus Sevelamer Hydrochloride for the Treatment of Hyperphosphatemia in Patients with End-Stage Renal Disease: A US Payer Perspective. Value Health. 2011 Dec;14(8):1002-9. PMID: 22152168.

13: Thongprasert S, Permsuwan U, Ruengorn C, et al.  Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer. Asia Pac J Clin Oncol. 2011 Dec;7(4):369-75. PMID: 22151987.

14: Nayak S, Roberts MS, Greenspan SL. Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med. 2011 Dec 6;155(11):751-61. PMID: 22147714.

15: Galper BZ, Moran A, Coxson PG, et al. Using Stress Testing to Guide Primary Prevention of Coronary Heart Disease among Intermediate-Risk Patients: A Cost-effectiveness Analysis. Circulation. 2011 Dec 5. [Epub ahead of print] PMID: 22144567.

16: Squires H, Simpson E, Meng Y, et al. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technol Assess. 2011 Dec;15(40):1-210. PMID: 22142554.

17: Lee K, Chow P, Wu D, et al. An Economic Analysis between Entecavir and  Lamivudine for the Treatment of Chronic Hepatitis B in Hong Kong. J Gastroenterol Hepatol. 2011 Dec 6. [Epub ahead of print] PMID: 22141402.

18: Hall PS, McCabe C, Stein RC, Cameron D. Economic Evaluation of Genomic Test-Directed Chemotherapy for Early-Stage Lymph Node-Positive Breast Cancer. J Natl Cancer Inst. 2011 Dec 2. [Epub ahead of print] PMID: 22138097.

19: Postmus D, Abdul Pari AA, Jaarsma T, et al. A trial-based economic evaluation of 2 nurse-led disease management programs in heart failure. Am Heart J. 2011 Dec;162(6):1096-104. PMID: 22137084.

20: Wang TS, Cheung K, Farrokhyar F, et al. Would scan, but which scan? A cost-utility analysis to optimize preoperative imaging for primary hyperparathyroidism. Surgery. 2011 Dec;150(6):1286-94. PMID: 22136852.

21: McKenna C, Maund E, Sarowar M, et al. Dronedarone for the Treatment of Atrial Fibrillation: A NICE Single Technology Appraisal. Pharmacoeconomics. 2011 Dec 2. [Epub ahead of print] PMID: 22136303.

22: McGarry LJ, Pawar VS, Parekh HH, et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology. 2011 Dec 2. [Epub ahead of print] PMID: 22135116.

23: Calvo Aller E, Maroto P, Kreif N, et al. Cost-effectiveness evaluation of sunitinib  as first-line targeted therapy for metastatic renal cell carcinoma in Spain. Clin Transl Oncol. 2011 Dec;13(12):869-77. PMID: 22126730.

24: Shauver MJ, Clapham PJ, Chung KC. An economic analysis of outcomes and complications of treating distal radius fractures in the elderly. J Hand Surg Am. 2011 Dec;36(12):1912-1918.e3. PMID: 22123045.

25: Joshi JK, Ouyang B, Prabhakaran S. Should TIA patients be hospitalized or referred to a same-day clinic?: A decision analysis. Neurology. 2011 Dec 13;77(24):2082-8. PMID: 22094477.

26: Baker TM, Goh Jo W, Johnston A, Falvey H, et al. Cost-effectiveness analysis of valsartan versus losartan and the effect of switching. J Med Econ. 2011 Dec 5. [Epub ahead of print] PMID: 22084957.

27: Carlos F, Ramírez-Gámez J, Dueñas H, et al. Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico. J Med Econ. 2011 Dec 5. [Epub ahead of print] PMID: 22082033.

28: Dakin H, Sherman M, Fung S, Fidler C, Bentley A. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a canadian public payer perspective. Pharmacoeconomics. 2011 Dec 1;29(12):1075-91. PMID: 22077579.

29: Díez-Domingo J, Ridao-López M, Gutiérrez-Gimeno MV, et al. Pharmacoeconomic assessment of implementing  a universal PCV-13 vaccination programme in the Valencian public health system (Spain). Vaccine. 2011 Dec 6;29(52):9640-8. PMID:22027484.

30: Lock K, Wilson K, Murphy D, et al. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2011 Dec;12(17):2613-26 PMID: 22017336.

31: Cahill AG, Odibo AO, Stout MJ, et al. Magnesium sulfate therapy for the prevention of cerebral palsy in preterm infants: a decision-analytic and economic analysis. Am J Obstet Gynecol. 2011 Dec;205(6):542.e1-7. PMID: 22000669.

32: Straub N, Grunert P, von Kries R, et al. Health economic potential of early nutrition programming: a model calculation of long-term reduction in blood  pressure and related morbidity costs by use of long-chain polyunsaturated fatty acid-supplemented formula. Am J Clin Nutr. 2011 Dec;94(6):2030S-5S. PMID: 21974892.

33: Dickson R, Bagust A, Boland A, et al. Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy: A NICE Single Technology Appraisal. Pharmacoeconomics. 2011 Dec 1;29(12):1051-62. PMID: 21967156.

34: Ekers D, Godfrey C, Gilbody S, et al. Cost utility of behavioural activation delivered by the non-specialist. Br J Psychiatry. 2011 Dec;199:510-1.  PMID: 21947655.

35: Fritzell P, Ohlin A, Borgström F. Cost-Effectiveness of Balloon Kyphoplasty Versus Standard Medical Treatment in Patients With Osteoporotic Vertebral Compression Fracture: A Swedish Multicenter Randomized Controlled Trial With 2-Year Follow-up. Spine (Phila Pa 1976). 2011 Dec 15;36(26):2243-51. PMID: 21912321.

36: Sud S, Mittmann N, Cook DJ, et al. Screening and prevention of venous thromboembolism in critically ill patients: a decision analysis and economic evaluation. Am J Respir Crit Care Med. 2011 Dec 1;184(11):1289-98.  PMID: 21868500.

37: Tran-Duy A, Boonen A, van de Laar MA, et al. A discrete event modelling framework for simulation of long-term outcomes of sequential treatment strategies for ankylosing spondylitis. Ann Rheum Dis. 2011 Dec;70(12):2111-8.  PMID: 21857027.

38: Kowada A. Cost-effectiveness of interferon-γ release assay versus chest X-ray for tuberculosis screening of employees. Am J Infect Control. 2011 Dec;39(10):e67-72.  PMID: 21839543.

39: Tsuchiya T, Fukuda T, Furuiye M, et al. Pharmacoeconomic analysis of consolidation therapy with pemetrexed after first-line chemotherapy for non-small cell lung cancer. Lung Cancer. 2011 Dec;74(3):521-8. PMID: 21570734.

40: Botteman MF, Meijboom M, Foley I, et al. Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom. Eur J Health Econ. 2011 Dec;12(6):575-88. PMID: 20809091.

By James D. Chambers

By CEA Registry Team on 10/17/2011 8:53 AM

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1. Waaler Bjørnelv GM, Frihagen F, Madsen JE, et al. Hemiarthroplasty compared to internal fixation with percutaneous cannulated screws as treatment of displaced femoral neck fractures in the elderly: cost-utility analysis performed alongside a randomized, controlled trial. Osteoporos Int. 2011 Oct 14. [Epub ahead of print] PubMed PMID: 21997224.

2. Raman V, McWilliams ET, Holmberg SR, et al. Economic analysis of the use of coronary calcium scoring as an alternative to stress ECG in the non-invasive diagnosis of coronary artery disease. Eur Radiol. 2011 Oct 13. [Epub ahead of print] PubMed PMID: 21993982.

3. Wu B, Chen H, Shen J, Ye M. Cost-Effectiveness of Adding Rh-Endostatin to First-Line Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer in China. Clin Ther. 2011 Oct 11. [Epub ahead of print] PubMed PMID: 21992806.

4. Sun SX, Marynchenko M, Banerjee R, et al. Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD. J Med Econ. 2011 Oct 12. [Epub ahead of print] PubMed PMID: 21992217.

5. Conly J, Clement F, Tonelli M, et al. Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk. CMAJ. 2011 Oct 11. [Epub ahead of print] PubMed PMID: 21989469.

6. Gidwani R, Pashos CL, Khan ZM, et al. A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes. J Med Econ. 2011 Oct 11. [Epub ahead of print] PubMed PMID: 21988635.

7. van Kempen BJ, Spronk S, Koller MT, et al. Comparative effectiveness and cost-effectiveness of computed tomography screening for coronary artery calcium in asymptomatic individuals. J Am Coll Cardiol. 2011 Oct 11;58(16):1690-701. PubMed PMID: 21982314.

8. Chen NC, Shauver MJ, Chung KC. Cost-Effectiveness of Open Partial Fasciectomy, Needle Aponeurotomy, and Collagenase Injection for Dupuytren Contracture. J Hand Surg Am. 2011 Oct 5. [Epub ahead of print] PubMed PMID: 21981831.

9. Robotham JV, Graves N, Cookson BD, et al. Screening, isolation, and decolonisation strategies in the control of meticillin resistant Staphylococcus aureus in intensive care units: cost effectiveness evaluation. BMJ. 2011 Oct 5;343:d5694. PubMed PMID: 21980062

10. Hagenmeyer EG, Koltermann KC, Dippel FW, et al. Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes: a systematic review. Cost Eff Resour Alloc. 2011 Oct 6;9(1):15. [Epub ahead of print] PubMed PMID: 21978524.

11. Straub N, Grunert P, von Kries R, et al. Health economic potential of early nutrition programming: a model calculation of long-term reduction in blood pressure and related morbidity costs by use of long-chain polyunsaturated fatty acid-supplemented formula. Am J Clin Nutr. 2011 Oct 5. [Epub ahead of print] PubMed PMID: 21974892.

12. Klarenbach S, Cameron C, Singh S, et al. Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately  controlled on metformin. CMAJ. 2011 Oct 3. [Epub ahead of print] PubMed PMID: 21969406.

13. Dickson R, Bagust A, Boland A, et al. Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy: A NICE Single Technology Appraisal. Pharmacoeconomics. 2011 Oct 3. [Epub ahead of print] PubMed PMID: 21967156.

14. McGuire KJ, Chacko AT, Bernstein J. Cost-effectiveness of Teaching Hospitals for the Operative Management of Hip Fractures. Orthopedics. 2011 Oct 5;34(10):e598-601. doi: 10.3928/01477447-20110826-17. PubMed PMID: 21956051.

15. Pham B, Stern A, Chen W, et al. Preventing Pressure Ulcers in Long-term Care: A Cost-effectiveness Analysis. Arch Intern Med. 2011 Oct 13. [Epub ahead of print] PubMed PMID: 21949031.

16. Monksfield P, Jowett S, Reid A, et al. Cost-effectiveness Analysis of the Bone-Anchored Hearing Device. Otol Neurotol. 2011 Oct;32(8):1192-7. PubMed PMID: 21909045.

17. Mäklin S, Malmivaara A, Linna M, et al. Cost-utility of bariatric surgery for morbid obesity in Finland. Br J Surg. 2011 Oct;98(10):1422-9. PubMed PMID: 21887777.

18. Lovibond K, Jowett S, Barton P, et al. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modeling study. Lancet. 2011 Oct 1;378(9798):1219-30. Epub 2011 Aug 23. PubMed PMID:21868086.

19. Lubowitz JH, Appleby D. Cost-effectiveness analysis of the most common orthopaedic surgery procedures: knee arthroscopy and knee anterior cruciate ligament reconstruction. Arthroscopy. 2011 Oct;27(10):1317-22. Epub 2011 Aug 19. PubMed PMID: 21855268.

20. Tilson L, Jit M, Schmitz S, et al. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland. Vaccine. 2011 Oct 6;29(43):7463-73. Epub 2011 Aug 5.  PubMed PMID: 21821085.

21. Giardina S, Pane B, Spinella G, et al. An economic evaluation of an abdominal aortic aneurysm screening program in Italy. J Vasc Surg. 2011 Oct;54(4):938-46. Epub 2011 Aug 6. PubMed PMID: 21820837.

22. Blank PR, Moch H, Szucs TD, et al. KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective. Clin Cancer Res. 2011 Oct 1;17(19):6338-46. Epub 2011 Aug 1. PubMed PMID:21807639.

23. Chan AL, Leung HW, Huang SF. Cost effectiveness of cetuximab concurrent with radiotherapy for patients with locally advanced head and neck cancer in Taiwan: a decision-tree analysis. Clin Drug Investig. 2011 Oct 1;31(10):717-26. PubMed PMID:21744880.

24. Hiligsmann M, Reginster JY. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in belgium. Pharmacoeconomics. 2011 Oct 1;29(10):895-911. PubMed PMID:21692551.

25. Ercolani G, Cucchetti A, Cescon M, et al. Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases. Eur J Cancer. 2011 Oct;47(15):2291-8. Epub 2011 Jun 7. PubMed PMID: 21652204.

26. Woodhall SC, Jit M, Soldan K, et al; on behalf of the QOLIGEN study group. The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK. Sex Transm Infect. 2011 Oct;87(6):458-463. Epub 2011 Jun 2. PubMed PMID:21636616.

27. van den Akker ME, Arts MP, van den Hout WB, et al. Tubular Diskectomy vs Conventional Microdiskectomy for the Treatment of Lumbar Disk-Related Sciatica: Cost Utility Analysis Alongside a Double-Blind Randomized Controlled Trial. Neurosurgery. 2011 Oct;69(4):829-36. PubMed PMID: 21623248.

28. Kanis JA, Cooper C, Hiligsmann M, et al. Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int. 2011 Oct;22(10):2565-73. Epub 2011 May 27. PubMed PMID: 21617992.

29. Taylor M, Leonardi-Bee J, Agboola S, et al. Cost effectiveness of interventions to reduce relapse to smoking following smoking cessation. Addiction. 2011 Oct;106(10):1819-26. Epub 2011 Jul 27. PubMed PMID: 21561499.

30. Morris S, Morris TP, McGregor AH, et al. Function after spinal treatment, exercise, and rehabilitation: cost-effectiveness analysis based on a randomized controlled trial. Spine (Phila Pa 1976). 2011 Oct 1;36(21):1807-14. PubMed PMID: 21505377.

31. Thijssen AS, Broeders IA, de Wit GA, et al. Cost-effectiveness of proton pump inhibitors versus laparoscopic Nissen fundoplication for patients with gastroesophageal reflux disease: a systematic review of the literature. Surg Endosc. 2011 Oct;25(10):3127-34. Epub 2011 Apr 13. PubMed PMID: 21487859.

32. Neovius K, Buesch K, Sandström K, et al. Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden. Acta Paediatr. 2011 Oct;100(10):1306-14. Epub 2011 May 13. PubMed PMID: 21477089.

33. Bøhmer E, Kristiansen IS, Arnesen H, et al. Health and cost consequences of early versus late invasive strategy after thrombolysis for acute myocardial infarction. Eur J Cardiovasc Prev Rehabil. 2011 Oct;18(5):717-23. Epub 2011 Feb 18. PubMed PMID: 2145059

By James D. Chambers

By CEA Registry Team on 10/3/2011 7:52 AM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials.

1. Resch B, Sommer C, Nuijten MJ, et al. Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus Infection in High-risk Children, Based on Long-term Epidemiologic Data From Austria. Pediatr Infect Dis J. 2011 Sep 28. [Epub ahead of print] PubMed PMID: 21960187.

2. Shiroiwa T, Fukuda T, Shimozuma K. Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial. Br J Cancer. 2011 Sep 29. [Epub ahead of print] PubMed PMID: 21959871.

3. Parker SL, Adogwa O, Davis BJ, et al. Cost-utility Analysis of Minimally Invasive Versus Open Multilevel Hemilaminectomy for Lumbar Stenosis. J Spinal Disord Tech. 2011 Sep 28. [Epub ahead of print] PubMed PMID: 21959840.

4. Cooper MS, Palmer AJ, Seibel MJ. Cost-effectiveness of the Concord Minimal Trauma Fracture Liaison service, a prospective, controlled fracture prevention study. Osteoporos Int. 2011 Sep 28. [Epub ahead of print] PubMed PMID: 21953475.

5. Jit M, Chapman R, Hughes O, et al. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ. 2011 Sep 27;343:d5775. PubMed PMID: 21951758.

6. Valentine WJ, Jendle J, Saraheimo M, et al. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with Insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands. Diabet Med. 2011 Sep 27. [Epub ahead of print] PubMed PMID: 21951030.

7. Pham B, Stern A, Chen W, et al. Preventing Pressure Ulcers in Long-term Care: A Cost-effectiveness Analysis. Arch Intern Med. 2011 Sep 26. [Epub ahead of print] PubMed PMID: 21949031.

8. Retèl VP, Joore MA, van Harten WH. Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance. Breast Cancer Res Treat. 2011 Sep 24. [Epub ahead of print] PubMed PMID: 21947677.

9. Ekers D, Godfrey C, Gilbody S, et al. Cost utility of behavioural activation delivered by the non-specialist. Br J Psychiatry. 2011 Sep 22. [Epub ahead of print] PubMed PMID: 21947655.

10. Bogaards JA, Coupé VM, Meijer CJ, et al. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands. Vaccine. 2011 Sep 22. [Epub ahead of print] PubMed PMID: 21945961.

11. Marwick TH, Scuffham PA, Hunink MG. Selection for early surgery in asymptomatic mitral regurgitation: A Markov model. Int J Cardiol. 2011 Sep 24. [Epub ahead of print] PubMed PMID: 21945713.

12. Robberstad B, Frostad CR, Akselsen PE, et al. Economic evaluation of second generation pneumococcal conjugate vaccines in Norway. Vaccine. 2011 Sep 20. [Epub ahead of print] PubMed PMID: 21945264.

13. Sadique Z, Grieve R, Harrison DA, et al. Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice? Crit Care. 2011 Sep 26;15(5):R228. [Epub ahead of print] PubMed PMID: 21943177.

14. Woods B, Paracha N, Scott DA, et al. Raltirexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma. Lung Cancer. 2011 Sep 19. [Epub ahead of print] PubMed PMID: 21937141.

15. Sopina E, Ashton T. Cost-effectiveness of a cervical screening program with human papillomavirus vaccine. Int J Technol Assess Health Care. 2011 Sep 22:1-8.  [Epub ahead of print] PubMed PMID: 21936972.

16. Tran BX, Ohinmaa A, Duong AT, et al. Cost-effectiveness of methadone maintenance treatment for HIV-positive drug users in Vietnam. AIDS Care. 2011 Sep 22. [Epub ahead of print] PubMed PMID: 21936718.

17. Zhang J, Denton BT, Balasubramanian H, et al. Optimization of PSA Screening Policies: A Comparison of the Patient and Societal Perspectives. Med Decis Making. 2011 Sep 20. [Epub ahead of print] PubMed PMID: 21933990.

18. Bjerklund Johansen TE, Baker TM, et al. Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial. BJU Int. 2011 Sep 20. [Epub ahead of print] PubMed PMID:21933326.

19. Cipriano LE, Levesque BG, Zaric GS, et al. Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease. Inflamm Bowel Dis. 2011 Sep 16.[Epub ahead of print] PubMed PMID: 21928375.

20. Hornberger J, Reyes C, Shewade A, et al. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia. Leuk Lymphoma. 2011 Sep 19. [Epub ahead of print] PubMed PMID: 21824050.

21. Blank PR, Moch H, Szucs TD, et al. KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective. Clin Cancer Res. 2011 Sep 20. [Epub ahead of print] PubMed PMID:21807639.

By James D. Chambers

By CEA Registry Team on 9/30/2011 7:45 PM

To continue the series of blogs summarizing the 2010 cost-utility literature recently added to the CEA Registry, here we focus on the type of intervention subject to cost-effectiveness analysis.

Among the 331 cost-utility studies published in 2010, approximately 32% account for pharmaceutical interventions followed by screening interventions (12%) (Figure 1). However, despite remaining the most common type of intervention evaluated, the percentage of studies evaluating pharmaceuticals was down from over 47% in previous years (Figure 2)

Figure 1: CUAs by interventions for 2010 (n=331)

Figure 2: CUAs by interventions from 1976-2010 (n=2735)

- Teja Thorat and Peter Neumann

By CEA Registry Team on 9/26/2011 9:33 AM

We recently posted on the latest updates to the Tufts CEA Registry, including the 331 articles added in 2010. Here we provide some additional data. Figure 1 shows the journals that have contributed the most 2010 articles to the Registry. The journal with highest frequency was Pharmacoeconomics (5.1%) followed by Value in Health (4.8%), Journal of Medical Economics (3.6%), Current Medical Research & Opinion (2.7%), Vaccine (2.4%) and BMJ (2.1%). 


Figure 1: CUAs by journal for 2010 (n=331)

Figure 2 displays the journals that have contributed cost-utility articles to the Registry from 1976 through 2010 (n=2735). Pharmacoeconomics has been the most frequent contributor, followed by Value in Health, International Journal of Technology Assessment in Health Care, Current Medical Research & Opinion, and Annals of Internal Medicine.

Figure 2: CUAs by journal from 1976-2010 (n=2735)

By Teja Thorat and Peter Neumann

By CEA Registry Team on 9/16/2011 5:52 PM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials.

1: Rosas SE, Feldman HI. Synthetic Vascular Hemodialysis Access Versus Native Arteriovenous Fistula: A Cost-Utility Analysis. Ann Surg. 2011 Sep 13. [Epub ahead of print] PubMed PMID: 21918428.

2: Nelson RE, Saltzman GM, Skalabrin EJ, et al. The cost-effectiveness of telestroke in the treatment of acute ischemic stroke. Neurology. 2011 Sep 14. [Epub ahead of print] PubMed PMID: 21917781.

3: Lavelle TA, Uyeki TM, Prosser LA. Cost-Effectiveness of Oseltamivir Treatment for Children with Uncomplicated Seasonal Influenza. J Pediatr. 2011 Sep 12. [Epub ahead of print] PubMed PMID: 21917267.

4: McQueen RB, Ellis SL, Campbell JD, et al. Cost-Effectiveness of Continuous Glucose Monitoring and Intensive Insulin Therapy for Type 1 Diabetes.  Cost Eff Resour Alloc. 2011 Sep 14;9(1):13.PubMed PMID:21917132.

5: Viney R, Norman R, King MT, et al. Time Trade-Off Derived EQ-5D Weights for Australia. Value Health. 2011 Sep-Oct;14(6):928-36. PubMed PMID: 21914515.

6: Vegter S, Tolley K, Keith MS, et al. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis. Value Health. 2011 Sep-Oct;14(6):852-8. Epub 2011 Jun 23. PubMed PMID: 21914505.

7: Casciano R, Chulikavit M, Di Lorenzo G, et al. Economic Evaluation of Everolimus versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line Sunitinib. Value Health. 2011 Sep-Oct;14(6):846-51.. PubMed PMID: 21914504.

8: Goulart B, Ramsey S. A Trial-Based Assessment of the Cost-Utility of Bevacizumab and Chemotherapy versus Chemotherapy Alone for Advanced Non-Small Cell Lung Cancer. Value Health. 2011 Sep-Oct;14(6):836-45. Epub 2011 Jun 24. PubMed PMID: 21914503.

9: Clements KM, Chancellor J, Nichol K, et al. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States. Value Health. 2011 Sep-Oct;14(6):800-11. PubMed PMID: 21914499.

10: Epstein D, Sutton A. Modelling correlated clinical outcomes in health technology appraisal. Value Health. 2011 Sep-Oct;14(6):793-9. Epub 2011 Jun 25. PubMed PMID: 21914498.

11: Fritzell P, Ohlin A, Borgström F. Cost-Effectiveness of Balloon Kyphoplasty (BKP) vs. Standard Medical Treatment in Patients with Osteoporotic Vertebral Compression Fracture - a Swedish Multicenter RCT with Two Year FU. Spine (Phila Pa 1976). 2011 Sep 8. [Epub ahead of print] PubMed PMID: 21912321.

12: Ananthakrishnan AN, Hur C, Korzenik JR. Certolizumab Pegol Compared to Natalizumab in Patients with Moderate to Severe Crohn's Disease: Results of a Decision Analysis. Dig Dis Sci. 2011 Sep 11. [Epub ahead of print] PubMed PMID: 21909990.

13: Lyth J, Andersson SO, Andrén O, et al. A decision support model for cost-effectiveness of radical prostatectomy in localized prostate cancer. Scand J Urol Nephrol. 2011 Sep 12. [Epub ahead of print] PubMed PMID: 21905981.

14: Doherty GA, Miksad RA, Cheifetz AS, et al. Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease. Inflamm Bowel Dis. 2011 Sep 8. doi: 10.1002/ibd.21904. [Epub ahead of print] PubMed PMID: 21905173.

15: Ternent L, Vale L, Boachie C, et al; for the Full-Thickness Macular Hole and Internal Limiting Membrane Peeling Study (FILMS) Group. Cost-effectiveness of internal limiting membrane peeling versus no peeling for patients with an idiopathic full-thickness macular hole: results from a randomised controlled trial. Br J Ophthalmol. 2011 Sep 6. [Epub ahead of print] PubMed PMID: 21900224.

16: Martin NK, Vickerman P, Miners A, et al. The cost-effectiveness of HCV antiviral treatment for injecting drug user populations. Hepatology. 2011 Sep 2. [Epub ahead of  print] PubMed PMID: 21898506.

17: Möller J, Nicklasson L, Murthy A. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib. J Med Econ. 2011 Sep 5. [Epub ahead of print] PubMed PMID: 21892856.

18: McMahon PM, Kong CY, Bouzan C, et al. Cost-Effectiveness of Computed Tomography Screening for Lung Cancer in the United States. J Thorac Oncol. 2011 Sep 1. [Epub ahead of print] PubMed PMID: 21892105.

19: Greenhalgh J, Bagust A, Boland A, et al. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. Health Technol Assess. 2011 Sep;15(31):1-178. PubMed PMID: 21888837.

20: Bojke L, Epstein D, Craig D, et al. Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis.  Rheumatology (Oxford). 2011 Sep;50 Suppl 4:iv39-iv47. PubMed PMID: 21859705.

21: Kattan MW, Earnshaw SR, McDade CL, et al. Cost Effectiveness of Chemoprevention for Prostate Cancer with Dutasteride in a High-Risk Population Based on Results from the REDUCE Clinical Trial. Appl Health Econ Health Policy.  2011 Sep 1;9(5):305-15. PubMed PMID:21875161.

22: Samuel S, Peskin B, Arondekar B, et al. Estimating health and economic benefits from using prescription omega-3 Fatty acids in patients with severe hypertriglyceridemia. Am J Cardiol. 2011 Sep 1;108(5):691-7. PubMed PMID: 21840433.

23: Praditsitthikorn N, Teerawattananon Y, Tantivess S, et al. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand. Pharmacoeconomics. 2011 Sep 1;29(9):781-806. PubMed PMID: 21838332.

24: Tyo KR, Rosen MM, Zeng W, et al. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: Comparing estimates for 7-valent, 10-valent, and 13-valent vaccines. Vaccine. 2011 Sep 2;29(38):6686-94. Epub 2011 Jul 13. PubMed PMID: 21745516.

25: Gupta N, Bansal A, Wani SB, et al. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis. Gastrointest Endosc. 2011 Sep;74(3):610-624.e2. Epub 2011 Jul 13. PubMed PMID:21741639.

26: Brown GC, Brown MM, Lieske HB, et al. Comparative effectiveness and cost-effectiveness of the implantable miniature telescope. Ophthalmology. 2011 Sep;118(9):1834-43. Epub 2011 Jul 2. PubMed PMID: 21723614.

27: Juusola JL, Brandeau ML, Long EF, et al. The cost-effectiveness of symptom-based testing and routine screening for acute HIV infection in men who have sex with men in the USA. AIDS. 2011 Sep 10;25(14):1779-87. PubMed PMID: 21716076.

28: Lesnock JL, Farris C, Krivak TC, et al. Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer. Gynecol Oncol. 2011 Sep;122(3):473-8. Epub 2011 Jun 12. PubMed PMID: 21665250

29: Kasteng F, Eriksson J, Sennfält K, Lindgren P. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. Acta Psychiatr Scand. 2011 Sep;124(3):214-25. Epub 2011 May 24. PubMed PMID: 21609324.

30: Benedict A, Figlin RA, Sandström P, et al. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. BJU Int. 2011 Sep;108(5):665-72. Epub 2011 Jan 25. PubMed PMID: 21265994.

31: Ruggeri M, Cicchetti A, Gasbarrini A. The cost-effectiveness of alternative strategies against HBV in Italy. Health Policy. 2011 Sep;102(1):72-80. Epub 2010  Oct 28. PubMed PMID: 21035229.

By James D. Chambers

By CEA Registry Team on 9/12/2011 8:35 AM

The CEA Registry is now fully updated with published cost-effectiveness articles through 2010. Data from 350 new articles were added to the Registry for 2010.

The Registry now contains the following:

•    2,735 cost-utility analyses on a wide variety of diseases and treatments
•    7,100 cost-effectiveness ratios
•    More than 10,000 utility weights

The CEA Registry has averaged roughly 350 new studies per year over the past few years, up from fewer than 100 per year prior to 2002 (Figure 1). 

Figure 1.  Growth in CUAs Over Time

Overall, researchers in the United States have contributed 43% of studies to the Registry, though the percent has declined somewhat over time (Figure 2).

Figure 2:  CUAs by country

In terms of types of interventions represented in the CEA Registry, pharmaceutical interventions account for 47% of the total, followed by surgical procedures (14%), care delivery (12%), medical procedure (12%) and screening (11.9%).  For studies published in 2010, pharmaceutical interventions account for 42% followed by screening (16%), surgical (12%), care delivery (10%) and medical procedure (10%).

The first wave of 2011 data should be available later this fall.

- Peter Neumann and Teja Thorat
 

By CEA Registry Team on 8/17/2011 9:18 AM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials.

1. Shearer DW, Kramer J, Bozic KJ, etal. Is Hip Arthroscopy Cost-effective for Femoroacetabular Impingement? Clin Orthop Relat Res. 2011 Aug 13. [Epub ahead of print] PMID: 21842295.

2. Wilson K, Hettle R, Marbaix S, et al. An economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain, Portugal, and Italy. Eur J Cardiovasc Prev Rehabil. 2011 Aug 12. [Epub ahead of print] PMID: 21840967.

3. Squires H, Tappenden P, Cooper K, et al. Cost-Effectiveness of Aspirin, Celecoxib, and Calcium Chemoprevention for Colorectal Cancer. Clin Ther. 2011 Aug 11. [Epub ahead of print] PubMed PMID: 21840057.

4. Kowada A. Cost-effectiveness of interferon-γ release assay versus chest X-ray for tuberculosis screening of employees. Am J Infect Control. 2011 Aug 11. [Epub ahead of print] PubMed PMID: 21839543.

5. Parsi K, Chambers CJ, Armstrong AW. Cost-effectiveness analysis of a patient-centered care model for management of psoriasis. J Am Acad Dermatol. 2011 Aug 9. [Epub ahead of print] PMID: 21835497.

6. Holmes MW, Goodacre S, Stevenson MD, et al. The cost-effectiveness of diagnostic management strategies for adults with minor head injury. Injury. 2011 Aug 9. [Epub ahead of print] PubMed PMID: 21835403.

7. Rive B, Aarsland D, Grishchenko M, et al. Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway. Int J Geriatr Psychiatry. 2011 Aug 10. [Epub ahead of print] PMID: 21834130.

8. Brook RH. The role of physicians in controlling medical care costs and reducing waste. JAMA. 2011 Aug 10;306(6):650-1. PubMed PMID: 21828329.

9. Cotton BA, Kao LS, Kozar R, Holcomb JB. Cost-utility analysis of levetiracetam and phenytoin for posttraumatic seizure prophylaxis. J Trauma. 2011 Aug;71(2):375-9. PubMed PMID: 21825941.

10. Hornberger J, Reyes C, Shewade A, et al. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia. Leuk Lymphoma. 2011 Aug 9. [Epub ahead of print] PubMed PMID: 21824050.

11. Maniadakis N, Ekman M, Calvert MJ, et al. Cost effectiveness of cardiac resynchronization therapy in Greece: an analysis based on the CArdiac REsychronization in Heart Failure trial. Europace. 2011 Aug 6. [Epub ahead of print] PubMed PMID: 21821852.

12. Tilson L, Jit M, Schmitz S, et al. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland. Vaccine. 2011 Aug 4. [Epub ahead of print] PubMed PMID: 21821085.

13. Giardina S, Pane B, Spinella G, et al. An economic evaluation of an abdominal aortic aneurysm screening program in Italy. J Vasc Surg. 2011 Aug 4. [Epub ahead of print] PMID: 21820837.

14. Shearer J, Green C, Counsell CE, et al. The impact of motor and non-motor symptoms on health state values in newly diagnosed idiopathic Parkinson's disease. J Neurol. 2011 Aug 5. [Epub ahead of print] PubMed PMID: 21818689.

15. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011 Aug 1. [Epub ahead of print] PubMed PMID: 21816193.

16. Blank PR, Moch H, Szucs TD, et al. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. Clin Cancer Res. 2011 Aug 1. [Epub ahead of print] PubMed PMID: 21807639.

17. Pandor A, Goodacre S, Harnan S, et al. Diagnostic management strategies for adults and children with minor head injury: a systematic review and an economic evaluation. Health Technol Assess. 2011 Aug;15(27):1-283. PubMed PMID: 21806873.

18. Hakkaart-van Roijen L, Goettsch WG, Ekkebus M, et al. The cost-effectiveness of an intensive treatment protocol for severe dyslexia in children. Dyslexia. 2011 Aug;17(3):256-67. PMID:21793122.

19. Tung CE, Win SS, Lansberg MG. Cost-effectiveness of tissue-type plasminogen activator in the 3- to 4.5-hour time window for acute ischemic stroke. Stroke. 2011 Aug;42(8):2257-62. Epub 2011 Jun 30. PubMed PMID: 21719767.

20. Zendejas B, Moriarty JP, O'Byrne J, et al. Cost-effectiveness of contralateral prophylactic mastectomy versus routine surveillance in patients with unilateral breast cancer. J Clin Oncol. 2011 Aug 1;29(22):2993-3000. Epub 2011 Jun 20. PubMed PMID: 21690472.

21. Khdour MR, Agus AM, Kidney JC, et al. Cost-utility analysis of a pharmacy-led self-management programme for patients with COPD. Int J Clin Pharm. 2011 Aug;33(4):665-73. PMID: 21643784.

22. Tosh JC, Wailoo AJ, Scott DL, et al. Cost-effectiveness of combination nonbiologic disease-modifying antirheumatic drug strategies in patients with early rheumatoid arthritis. J Rheumatol. 2011 Aug;38(8):1593-600. Epub 2011 May 15. PMID: 21572149.

23. Adogwa O, Parker SL, et al. Cost-effectiveness of transforaminal lumbar interbody fusion for Grade I degenerative spondylolisthesis. J Neurosurg Spine. 2011 Aug;15(2):138-43. Epub 2011 May 6. PubMed PMID: 21529203.

24. Chuang LH, Soares MO, Watson JM, et al; on behalf of the VenUS III team. Economic evaluation of a randomized controlled trial of ultrasound therapy for hard-to-heal venous leg ulcers. Br J Surg. 2011 Aug;98(8):1099-1106. Epub 2011 Apr 20. PMID: 21509750.

25. Scotland G, McLernon D, Kurinczuk J, et al. Minimising twins in in vitro fertilisation: a modelling study assessing the costs, consequences and cost-utility of elective single versus double embryo transfer over a 20-year time horizon. BJOG. 2011 Aug;118(9):1073-1083. Epub 2011 Apr 8. PubMed PMID: 21477172.

26. Miller SM, Goldstein JL, Gerson LB. Cost-Effectiveness Model of Endoscopic Biopsy for Eosinophilic Esophagitis in Patients With Refractory GERD. Am J Gastroenterol. 2011 Aug;106(8):1439-45. Epub 2011 Mar 29. PubMed PMID: 21448144.

27. Noah-Vanhoucke J, Green LE, Dinh TA, et al. Cost-effectiveness of chemoprevention of breast cancer using tamoxifen in a postmenopausal US population. Cancer. 2011 Aug 1;117(15):3322-31. Epub 2011 Mar 14. PubMed PMID: 21404271.

28. Bosmans JE, Pool JJ, de Vet HC, et al. Is behavioral graded activity cost-effective in comparison with manual therapy for patients with subacute neck pain?: an economic evaluation alongside a randomized clinical  trial. Spine (Phila Pa 1976). 2011 Aug 15;36(18):E1179-86. PMID: 21343847.

29. Leong RK, de Wachter SG, Joore MA, et al. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin. A treatment for patients with idiopathic overactive bladder. BJU Int. 2011 Aug;108(4):558-64. PMID: 21166750.

By James D. Chambers

By CEA Registry Team on 8/1/2011 9:34 AM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials.

1. Barton P, Andronis L, Briggs A, et al. Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study. BMJ. 2011 Jul 28;343:d4044. PubMed PMID: 21798967.

2. Yamamoto N, Mori R, Jacklin P, et al. Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis. BJOG. 2011 Jul 28. PubMed PMID: 21794070.

3. de Lima Lopes G Jr, Segel JE, Tan DS, et al. Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer. 2011 Jul 26. PubMed PMID: 21792863.

4. Dy CJ, McCollister KE, Lubarsky DA, et al. An economic evaluation of a systems-based strategy to expedite surgical treatment of hip fractures. J Bone Joint Surg Am. 2011 Jul 20;93(14):1326-34. PubMed PMID: 21792499.

5. Holland DP, Sanders GD, Hamilton CD, et al. Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection. PLoS One. 2011;6(7):e22276. Epub 2011 Jul 18. PubMed PMID: 21789248

6. Ananthakrishnan AN, Hur C, Juillerat P, et al. Strategies for the Prevention of Postoperative Recurrence in Crohn's Disease: Results of a Decision Analysis. Am J Gastroenterol. 2011 Jul 26. PubMed PMID: 21788991.

7. Mennini FS, Panatto D, Marcellusi A, et al. Time Trade-Off Procedure for Measuring Health Utilities Loss With Human Papillomavirus-Induced Diseases: A Multicenter, Retrospective, Observational Pilot Study in Italy. Clin Ther. 2011 Jul 23. PubMed PMID: 21788076.

8. Noyes K, Bajorska A, Chappel A, et al. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: A population-based study. Neurology. 2011 Jul 26;77(4):355-63. PubMed PMID: 21775734

9: Murphy JD, Chang DT, et al. Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer. Cancer. 2011 Jul 19. PubMed PMID: 21773972.

10. Aberg F, Mäklin S, Räsänen P, et al. Cost of a quality-adjusted life year in liver transplantation: The influence of indication and MELD score. Liver Transpl. 2011 Jul 18. PubMed PMID: 21770017.

11. Brent RJ. The effects of HIV medications on the quality of life of older adults in New York City. Health Econ. 2011 Jul 18. doi: 10.1002/hec.1774. PubMed PMID: 21766480.

12. Price D, Gray A, Gale R, et al. Cost-utility analysis of indacaterol in Germany: A once-daily maintenance bronchodilator for patients with COPD. Respir Med. 2011 Jul 15. PubMed PMID: 21764277.

13. Glazener C, Boachie C, Buckley B, et al. Urinary incontinence in men after formal one-to-one pelvic-floor muscle training following radical prostatectomy or transurethral resection of the prostate (MAPS): two parallel randomised controlled trials. Lancet. 2011 Jul 23;378(9788):328-37. PubMed PMID: 21741700.

By James D. Chambers

By CEA Registry Team on 7/27/2011 2:31 PM

July 28th is World Hepatitis Day.  In recognition, we searched the CEA Registry for estimates of cost-effectiveness of hepatitis C (HCV) screening (Table 1). 

Globally, hepatitis is a hugely burdensome disease with nearly 1 in 12 people suffering from hepatitis. [1]  If left undiagnosed and untreated, hepatitis can lead to disability, liver scarring, and liver cancer. 

The results of our search show a wide range of cost-effectiveness estimates for hepatitis screening, from dominant strategies (more effective and less costly than the comparator) to those that are dominated (less effective and more costly than the comparator).  Strategies that target people with risk factors for contracting hepatitis are the most cost-effective, including strategies targeting injection drug users and the prison population. 
 

Table 1. Cost-effectiveness of hepatitis C screening in a variety of circumstances

Reference
US$/QALY
Intervention      
Comparator      Target Population               
Tramarin 2008 Curr Pharm Des (PMID 18673188) Cost-Saving HCV serology every 6 month, lifelong No screening Injected Drug Users (IDUs) in the Veneto Region, Italy
 
Pereira 2000 Transfusion (11061853) Cost-Saving Screening blood for HCV using current protocols Screening blood for HCV using surrogate markers Blood transfusion recipients
Stein 2004 J Public Health (Oxf) (15044577) 50000 Screening for HCV No Screening Patients with history of drug use
Sutton 2008 J Viral Hepat (18637074) 120000 Screening for HCV Usual care -- symptomatic testing within community Prison population of England and Wales
Stein 2003 J Hepatol (14568266) 150000 Universal screening for HCV No screening    Adult patients attending genitourinary medicine clinics in England
Leal 1999 J Med Screen (10572842) 150000 Screening for HCV    Status quo IV drug users in contact with the health care system in South and West health regions of the UK.
Plunkett 2005 Am J Obstet Gynecol (15846195) 1.40E+06 HCV screening, treatment, and elective cesarean delivery No screening Asymptomatic, HIV-negative pregnant women without risk factors for HCV infection who received routine prenatal care in the US
Pereira 2000 Transfusion (11061853) 2.40E+06 Screening HCV using RNA testing added to current protocols Screening blood for HCV using current protocols Blood transfusion recipients
Plunkett 2005 Am J Obstet Gynecol (15846195) Dominated HCV screening and treatment    No screening Asymptomatic, HIV-negative pregnant women without risk factors who received routine prenatal care in the US
Singer 2001 Am J Med (11755504) Dominated Screening for HCV No screening Asymptomatic, average risk adults (HCV)

 

These findings are consistent with those in Cohen et al 2009. [2]  In certain circumstances screening offers tremendous value, increasing health while decreasing the overall cost of care.  However, in other circumstances screening strategies can be highly cost-ineffective, resulting in little or no health gain for the investment.  While screening offers great potential to increase health and generate cost-savings, it is important to target appropriate populations (e.g., those at risk).

You can find out more information regarding hepatitis, including information on prevention, diagnosis, and treatment at: http://www.worldhepatitisalliance.org.

By: Michael J. Cangelosi and James D. Chambers

References
[1] ELPA-info.org (2010) Avilable Online at:www.elpa-info.org
[2] Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? Health economics and the presidential candidates. N Engl J Med. 2008 Feb 14;358(7):661-3

By CEA Registry Team on 7/26/2011 8:12 AM

On July 19th, the Centers for Medicare and Medicaid Services (CMS) posted two proposed decision memos pertaining to screening on their website:  screening and behavioral counseling interventions in primary care to reduce alcohol misuse; and screening for depression in adults. [1] [2]

These proposed decisions are notable in that they include discussions of cost-effectiveness.

In both cases, CMS appeals to the Medicare Improvements for Patients and Providers Act (MIPPA) of 2008 (§1861(ddd)(2)) to justify inclusion of cost-effectiveness evidence: 

“Cost and cost-effectiveness studies were also searched (as part of the internal technology assessment), as §1861(ddd)(2) expressly authorizes the agency to “conduct an assessment of the relation between predicted outcomes and the expenditures for such services”.”

In both instances, the proposed decisions are consistent with the cost-effectiveness evidence.  The proposed decision for screening and counseling to reduce alcohol misuse included review of Solberg et al, 2008. [3] This study presented an analysis that estimated the intervention to be cost-saving from the societal perspective and to have a cost-effectiveness ratio of $1755/QALY saved from a health-system perspective.

The proposed decision for screening for depression in adults presented the findings of Simon et al, 2007. [4] The results showed that compared to usual care, screening using multicomponent depression management was dominant, accumulating 61 additional depression free days while accumulating savings of $314 per patient.

Given recent health reform legislation restricting the use of cost/QALYs [5], CMS’s review of a cost-utility study (Solberg et al) may come as a surprise.  Its inclusion is further explained through the following text:

Although this evaluation regarding the cost-effectiveness of screening for alcohol misuse used quality-adjusted life years (QALYs), CMS does not have and is not establishing in this proposed decision memorandum a coverage threshold for QALYs.  See 1182(e) of the Social Security Act.

Regular readers of this blog will be aware of other recent instances of CMS reviewing cost-effectiveness evidence for preventative care (here and here).  The new decisions seem to form something of a trend for CMS including cost-effectiveness evidence in their reviews for preventative care.

As blog readers also know, the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center maintains the Tufts NCD Database that includes detailed information on all NCDs from 1999 through 2011.

By James D. Chambers

References
1. Proposed Decision Memo for Screening and Behavioral Counseling Interventions in Primary Care to Reduce Alcohol Misuse (CAG-00427N). Available here
2. Proposed Decision Memo for Screening for Depression in Adults (CAG-00425N). Available here
3. Solberg L, Maciosek M and Edwards N.  Primary care intervention to reduce alcohol misuse ranking its health impact and cost effectiveness.  American Journal of Preventive Medicine 2008 February;34(2):143-152
4. Simon G, Katon W, Lin E, et al.  Cost-effectiveness of systematic depression treatment among people with diabetes mellitus.  Archives of General Psychiatry 2007 Januarry;64(1):65-72
5. Chambers JD, Neumann PJ.  US healthcare reform: implications for health economics and outcomes research.  Expert Rev Pharmacoecon Outcomes Res. 2010 Jun;10(3):215-6 Available here

 

By CEA Registry Team on 7/21/2011 7:31 AM

In a new paper, my colleagues and I review the literature on the cost-effectiveness of interventions for chronic kidney disease (CKD). [1]

We searched the Tufts Cost-Effectiveness Analysis Registry (www.cearegistry.org) and other sources and grouped the findings into three categories – stage 1–4 CKD, transplant and end-stage renal disease (ESRD). 

The results highlight the growing number of cost-effectiveness analyses available on interventions for CKD.  The study includes detail on 72 cost-utility analyses and 20 cost-effectiveness analyses (where outcomes are measured in terms of cost per life year gained). Many of the interventions identified are cost saving or cost-effective under conventional thresholds (e.g., $100,000 per QALY or life year gained). 

The study also shows the need to improve the methodological quality and usability of studies.  As we’ve noted in other research [2], there is variability in the methods used to estimate cost-effectiveness ratios.  In terms of usability, the studies identified sometimes omit important implementation barriers (e.g., limits in the number of organs for transplantation or patient education, or changes to the reimbursement system needed to encourage greater use of home hemodialysis).

Still, as CMS has moved to a bundled payment for ESRD, there will be a greater need to manage kidney disease patients efficiently.  That should mean a growing importance of cost-effectiveness analyses in the future.

By Peter J. Neumann

References
1. Menzin J, Lines LM, Weiner DE, Neumann PJ, Nichols C, Rodriquez L, Agodoa I, Mayne T.  A review of the Costs and Cost Effectiveness of Interventions in Chronic Kidney Disease.  Pharmacoeconomics. 2011
2. Neumann PJ, Greenberg D, Olchanski NV, Stone PW, Rosen AB.  Growth and quality of the cost-utility literature, 1976-2001. Value in Health. 2005;8(1):3–9.

By CEA Registry Team on 7/15/2011 8:42 AM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials.

1. Tyo KR, Rosen M, Zeng W, et al.  Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: Comparing estimates for 7-valent, 10-valent, and 13-valent vaccines. Vaccine. 2011 Jul 8. [Epub ahead of print] PubMed PMID: 21745516.

2. Chan AL, Leung HW, Huang SF. Cost Effectiveness of Cetuximab Concurrent with Radiotherapy for Patients with Locally Advanced Head and Neck Cancer in Taiwan: A Decision-Tree Analysis. Clin Drug Investig. 2011 Jul 12. [Epub ahead of print] PubMed PMID: 21744880.

3. Campbell HE, Epstein D, et al. The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. Eur  J Cancer. 2011 Jul 7. [Epub ahead of print] PubMed PMID: 21741831.

4. Glazener C, Boachie C, Buckley B, et al.  Urinary incontinence in men after formal one-to-one pelvic-floor muscle training following radical prostatectomy or transurethral resection of the prostate (MAPS): two parallel randomised controlled trials. Lancet. 2011 Jul 7. [Epub ahead of print] PubMed PMID: 21741700.

5. Gupta N, Bansal A, Wani SB, et al. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis. Gastrointest Endosc. 2011 Jul 7. [Epub ahead of print] PubMed PMID: 21741639.

6. Sullivan SD, Garrison LP, Rinde H, Kolberg J, Moler EJ. Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk score. J Med Econ. 2011 Jul 11. [Epub ahead of print] PubMed PMID: 21740291.

7. Sund B, Svensson L, Rosenqvist M, et al. Favourable cost-benefit in an early defibrillation programme using dual dispatch of ambulance and fire services in out-of-hospital cardiac arrest. Eur J Health Econ. 2011 Jul 8. [Epub ahead of  print] PubMed PMID: 21739334.

8. Kobelt G, Lekander I, Lang A, et al. Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment. Int J Technol Assess Health Care. 2011 Jul 8:1-8. [Epub ahead of print] PubMed PMID: 21736857.

9. Colquitt J, Jones J, Harris P, et al. Bone-anchored hearing aids (BAHAs) for people who are bilaterally deaf: a systematic review and economic evaluation. Health Technol Assess. 2011 Jul;15(26):1-200. PubMed PMID: 21729632.

10. Prenzler A, Yen L, Mittendorf T, von der Schulenburg JM. Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine. BMC Health Serv Res. 2011 Jul 5;11(1):157. [Epub ahead of print] PubMed PMID: 21729262.

11. Lowin J, Bergman A, Ray Chaudhuri K, et al. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK. J Med Econ. 2011 Jul 6. [Epub ahead of print] PubMed PMID: 21728911.

12. Schousboe JT, Kerlikowske K, Loh A, et al. Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med. 2011 Jul 5;155(1):10-20. PubMed  PMID: 21727289.

13. Spronk S, van Kempen BJ, Boll AP, et al. Cost-effectiveness of screening for abdominal aortic aneurysm in the Netherlands and Norway. Br J Surg. 2011 Jul 4. doi: 10.1002/bjs.7620. [Epub ahead of print] PubMed PMID: 21725968.

14. Cummins E, Asseburg C, Prasad M, et al. Cost effectiveness of golimumab for the treatment of active psoriatic arthritis. Eur J Health Econ. 2011 Jul 1. [Epub ahead of print] PubMed PMID: 21720868.

15. Davis JC, Marra CA, Robertson MC, et al. Sustained Economic Benefits of Resistance Training in Community-Dwelling Senior Women. J Am Geriatr Soc. 2011 Jul;59(7):1232-1237. Epub 2011 Jun 30. PubMed PMID: 21718265.

16. Juusola JL, Brandeau ML, Long EF, et al. The Cost-Effectiveness of Symptom-Based Testing and Routine Screening for Acute HIV Infection in Men Who Have Sex with Men in the United States. AIDS. 2011 Jul 8. [Epub ahead of print] PubMed PMID: 21716076.

17. Lazar LD, Pletcher MJ, Coxson PG, et al. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation. 2011 Jul 12;124(2):146-53. Epub 2011 Jun 27. PubMed PMID: 21709063.

18. Nherera L, Marks D, Minhas R, et al. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart. 2011 Jul;97(14):1175-81. PubMed PMID: 21685482.

19. Mueller D, Gandjour A. Cost Effectiveness of Secondary vs Tertiary Prevention for Post-Menopausal Osteoporosis. Appl Health Econ Health Policy. 2011 Jul 1;9(4):259-73. PubMed PMID: 21682353.

20. Luangasanatip N, Chaiyakunapruk N, Upakdee N, et al. Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study. Clin Drug Investig. 2011 Jul 1;31(7):493-505. PubMed PMID: 21627338.

21. Szucs TD, Kressig RW, Papageorgiou M, et al. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Hum Vaccin. 2011 Jul 1;7(7). [Epub ahead of print] PubMed PMID: 21606685.

22. Muntinghe FL, Vegter S, Verduijn M, et al. Using a genetic, observational study as a strategy to estimate the potential cost-effectiveness of pharmacological CCR5 blockade in dialysis patients. Pharmacogenet Genomics. 2011 Jul;21(7):417-25. PubMed PMID: 21597398.

23. Schipper LG, Kievit W, den Broeder AA, et al. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective. Rheumatology (Oxford). 2011 Jul;50(7):1320-30. Epub 2011 Mar 2. PubMed PMID: 21371999.

24. Naik S, Lundberg J, Kumar R, et al. Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden. Scand J Infect Dis. 2011 Jul;43(6-7):504-14. Epub 2011 Feb 18. PubMed PMID: 21332286.

25. Maes IH, Joore MA, Cima RF, et al. Assessment of Health State in Patients With Tinnitus: A Comparison of the EQ-5D and HUI Mark III. Ear  Hear. 2011 Jul-Aug;32(4):428-35. PubMed PMID: 21221004.

26. Werner EF, Han CS, Pettker CM, et al. Universal cervical-length screening to prevent preterm birth: a cost-effectiveness analysis. Ultrasound Obstet Gynecol. 2011 Jul;38(1):32-7. Epub 2011 May 24. PubMed PMID: 21157771.

27. Linde C, Mealing S, Hawkins N, et al; on behalf of the REVERSE study group. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction). Eur Heart J. 2011 Jul;32(13):1631-1639. Epub 2010 Nov 25. PubMed PMID: 21112898.

28. Fritzell P, Berg S, Borgström F, et al. Cost effectiveness of disc prosthesis versus lumbar fusion in patients with chronic low back pain: randomized controlled trial with 2-year follow-up. Eur Spine J. 2011 Jul;20(7):1001-1011. Epub 2010 Nov 5. PubMed PMID: 21053028.

29. Koffijberg H, Buskens E, Rinkel GJ. Aneurysm occlusion in elderly patients with aneurysmal subarachnoid haemorrhage: a cost-utility analysis. J Neurol Neurosurg Psychiatry. 2011 Jul;82(7):718-27. Epub 2009 Dec 3. PubMed PMID: 19965848.

By James D. Chambers

By CEA Registry Team on 7/11/2011 10:37 AM

The CEA Registry Team is pleased to announce that the Tufts Cost-Effectiveness Registry (www.cearegistry.org) is now updated with cost-utility studies published through 2010*. The Registry now includes information on the following:

  • 2,682 cost-utility articles
  • 7,080 ratios standardized cost-utility ratios
  • 9,800 utility weights


A brief breakdown of Registry contents:

Number of CUAs by study country:

US 1159 42.8
UK 455 17.0%
Canada 190 7.1%


By disease area:

Cardiovascular Disease 463 17.3%
Cancer 351 17.0%
Infectious Disease 284 10.6%


By top publishing journal:

Pharmacoeconomics 120 4.5%
Value Health 97 3.6%
Int J Assess Health Care 75 2.8%


By intervention:

Pharmaceutical 1243 46.4%
Surgical procedure 373 13.9%
Care Delivery 326 12.2%

Use the search box on the cearegistry.org website to search for information. Check back soon for highlights of the latest published cost-utility analyses and commentary of the latest news about value measurement in health care.

As always, we welcome and appreciate comments.

By CEA Registry Team

*Note: Some hard-to-retrieve 2010 articles are still in process and will be added soon.

By CEA Registry Team on 7/7/2011 9:54 AM

In a newly published paper Braithwaite and Mentor use data from the Tufts Cost-Effectiveness Analysis Registry (www.cearegistry.org) to analyze evidence of value for 17 cardiovascular health services. [1]

The paper acknowledging the usefulness of CEA Registry as well as some limitations, including the fact that the Registry does not report on the strength of the underlying clinical evidence, and the fact that analyses do not have “an expiration date” (i.e., interventions can and do become outmoded over time).  

The authors describe a new way to synthesize evidence from the Registry for use by consumers, payers, and other decision makers.  They provide a series of stepwise “filters” to take Registry data and develop a list of interventions with high quality evidence. 

The steps include, among other things, reviewing Registry studies with the Quality of Health Economic Studies (QHES) instrument, and reviewing each study for robustness of clinical effectiveness evidence and for nonobsolescence (by checking the most up-to-date clinical guidelines of a medical society).  The goal was to identify a limited number of cardiovascular health services that one can confidently say represents favorable value (under $100,000/QALY).

The list of high-value services includes:

• statins to prevent myocardial infarction (MI) for primary and secondary prevention;
• screening for and treatment of high blood pressure (diuretics or b-blockers and angiotensin-converting enzyme inhibitors in the case of diabetes) to prevent MI and stroke;
• warfarin sodium and low-molecular-weight heparin to prevent pulmonary emboli;
• implantable cardiac defibrillators for patients at high risk of sudden death;
• antiplatelet drugs (aspirin and clopidogrel bisulfate) to prevent future MI;
• b-blockers for patients who have had myocardial infarction warfarin to prevent future stroke in persons with nonvalvular atrial fibrillation;
• percutaneous procedures to relieve claudication symptoms procedures to relieve claudication symptoms.
 
See the paper for details.  The exercise shows the value of the CEA Registry and the value of exploring new methods for synthesizing cost-effectiveness evidence. 

By Peter J. Neumann

References:
1. Braithwaite RS, Mentor SM.  Identifying favorable-value cardiovascular health services.  Am J Manag Care.  2011;17(6):431-38.

By CEA Registry Team on 7/5/2011 9:36 AM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials. The CEA registry includes every cost-utility study published and indexed in Medline (through July 2010).

1. L J, Brandeau ML, Long EF, Owens DK, et al. The Cost-Effectiveness of Symptom-Based Testing and Routine Screening for Acute HIV Infection in Men Who Have Sex with Men in the United States. AIDS. 2011 Jun 29. [Epub ahead of print] PubMed PMID: 21716076.

2. Ganguli A, Wang J, Gourley DR. Does combining antiretroviral agents in a single dosage form enhance quality of life of HIV/AIDS patients? A cost-utility study. Res Social Adm Pharm. 2011 Jun 27. [Epub ahead of print] PubMed PMID: 21712147.

3. Zhang Y, Kivipelto M, Solomon A, et al. Cost-Effectiveness of a Health Intervention Program with Risk Reductions for Getting Demented: Results of a Markov Model in a Swedish/Finnish Setting. J Alzheimers Dis. 2011 Jun 27. [Epub ahead of print] PubMed PMID: 21709377.

4. Lazar LD, Pletcher MJ, Coxson PG, et al. Cost-Effectiveness of Statin Therapy for Primary Prevention in a Low-Cost Statin Era. Circulation. 2011 Jun 27. [Epub ahead of print] PubMed PMID: 21709063.

5. Bertoldi EG, Rohde LE, Zimerman LI, et al CA. Cost-effectiveness of cardiac resynchronization therapy in patients with heart failure: The perspective of a middle-income country's public health system. Int J Cardiol. 2011 Jun 23. [Epub ahead of print] PubMed PMID: 21704396.

6. Delea TE, Tappenden P, Sofrygin O, et al. Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab.  Eur J Health Econ. 2011 Jun 24. [Epub ahead of print] PubMed PMID: 21701940.

7. Eye Care Comparative Effectiveness Research Team (ECCERT). Cost-effectiveness of cataract surgery in Japan. Jpn J Ophthalmol. 2011 Jun 22. [Epub ahead of print] PubMed PMID: 21695383.

8. Park K, Perez F, Tsai R, et al. Cost-effectiveness Analysis of Adjunct VSL#3 Therapy Versus Standard Medical Therapy in Pediatric Ulcerative Colitis. J Pediatr Gastroenterol Nutr. 2011 Jun 17. [Epub ahead of print] PubMed PMID: 21694634.

9. Scott GW, Scott HM, O'Keeffe KM, et al. Insomnia - treatment pathways, costs and quality of life. Cost Eff Resour Alloc. 2011 Jun 21;9(1):10. [Epub ahead of print] PubMed PMID: 21693060.

10. Hiligsmann M, Reginster JY. Cost Effectiveness of Denosumab Compared with Oral Bisphosphonates in the Treatment of Post-Menopausal Osteoporotic Women in Belgium. Pharmacoeconomics. 2011 Jun 21. [Epub ahead of print] PubMed PMID: 21692551.

11. Zendejas B, Moriarty JP, O'Byrne J, et al. Cost-Effectiveness of Contralateral Prophylactic Mastectomy Versus Routine Surveillance in Patients With Unilateral Breast Cancer. J Clin Oncol. 2011 Jun 20. [Epub ahead of print] PubMed PMID: 21690472.

By James D. Chambers

By CEA Registry Team on 6/16/2011 9:16 AM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials. The CEA registry includes every cost-utility study published and indexed in Medline (through July 2010).

1. Menzin J, Lines LM, Weiner DE, et al. A Review of the Costs and Cost Effectiveness of Interventions in Chronic Kidney Disease: Implications for Policy. Pharmacoeconomics. 2011 Jun 14. [Epub ahead of print] PubMed PMID: 21671688.

2. Wiens A, Venson R, Correr CJ, et al. Cost-effectiveness of telbivudine versus lamivudine for chronic hepatitis B. Braz J Infect Dis. 2011 Jun;15(3):225-30. PubMed PMID: 21670922.

3. Crespin DJ, Federspiel JJ, Biddle AK, et al. Ticagrelor versus Genotype-Driven Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndrome: A Cost-Effectiveness Analysis. Value Health. 2011 Jun;14(4):483-91. Epub 2011 May 19. PubMed PMID: 21669373.

4. Briel M, Sprague S, Heels-Ansdell D, et al. Economic Evaluation of Reamed versus Unreamed Intramedullary Nailing in Patients with Closed and Open Tibial Fractures: Results from the Study to Prospectively Evaluate Reamed Intramedullary Nails in Patients with Tibial Fractures (SPRINT). Value Health. 2011 Jun;14(4):450-7. Epub 2011 May 25. PubMed PMID: 21669369.

5. Lesnock JL, Farris C, Krivak TC, et al. Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer. Gynecol Oncol. 2011 Jun 11. [Epub ahead of print] PubMed PMID: 21665250.

6. Rozenbaum MH, Mangen MJ, Giaquinto C, et al. Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model. BMC Public Health. 2011 Jun 10;11(1):462. [Epub ahead of print] PubMed PMID: 21663620.

7. Rodríguez Barrios JM, Pérez Alcántara F, Crespo Palomo C, et al. The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications. Eur J Health Econ. 2011 Jun 10. [Epub ahead of print] PubMed PMID: 21660565.

8. Borget I, Cadranel J, Pignon JP, et al. Comparative cost-effectiveness of three strategies for guiding second-line erlotinib initiation in non small-cell lung cancer: a French prospective multicenter study (ERMETIC Project Part 3). Eur Respir J. 2011 Jun 9. [Epub ahead of print] PubMed PMID: 21659409.

9. Ercolani G, Cucchetti A, Cescon M, et all. Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases. Eur J Cancer. 2011 Jun 6. [Epub ahead of print] PubMed PMID: 21652204.

10. Beard SM, Roskell N, Le TK, et al. Cost effectiveness of duloxetine in the treatment of fibromyalgia in the United States. J Med Econ. 2011 Jun 9. [Epub ahead of print] PubMed PMID: 21651426.

11. Lehtonen L, Rautava L, Korvenranta E, et al. PERFECT preterm infant study. Ann Med. 2011 Jun;43 Suppl 1:S47-53. PubMed PMID: 21639718.

12. Khdour MR, Agus AM, Kidney JC, et al. Cost-utility analysis of a pharmacy-led self-management programme for patients with COPD. Int J Clin Pharm. 2011 Jun 4. [Epub ahead of print] PubMed PMID: 21643784.

13. Parker SL, Fulchiero EC, Davis BJ, et al. Cost-effectiveness of multilevel hemilaminectomy for lumbar stenosis-associated radiculopathy. Spine J. 2011 Jun 3. [Epub ahead of print] PubMed PMID: 21641874.

14. Glazener C, Boachie C, Buckley B, et al. Conservative treatment for urinary incontinence in Men After Prostate Surgery (MAPS): two parallel randomised controlled trials. Health Technol Assess. 2011 Jun;15(24):1-296. PubMed PMID: 21640056.

15. Hayes AJ, Clarke PM, Voysey M, Keech A. Simulation of Quality-Adjusted Survival in Chronic Diseases: An Application in Type 2 Diabetes. Med Decis Making. 2011 Jun 2. [Epub ahead of print] PubMed PMID: 21636740.

16. Woodhall SC, Jit M, Soldan K, et al; on behalf of the QOLIGEN study group. The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK. Sex Transm Infect. 2011 Jun 2. [Epub ahead of print] PubMed PMID: 21636616.

17. Clark F, Jackson J, Carlson M, et al. Effectiveness of a lifestyle intervention in promoting the well-being of independently living older people: results of the Well Elderly 2 Randomised Controlled Trial. J Epidemiol Community Health. 2011 Jun 2. [Epub ahead of print] PubMed PMID: 21636614.

18. Pietzsch JB, Garner A, Cipriano LE, et al. An Integrated Health-Economic Analysis of Diagnostic and Therapeutic Strategies in the Treatment of Moderate-to-Severe Obstructive Sleep Apnea. Sleep. 2011 Jun 1;34(6):695-709. PubMed PMID: 21629357; PubMed Central PMCID: PMC3098944.

19. Goto S, Komaba H, Moriwaki K, et al. Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. Clin J Am Soc Nephrol. 2011 Jun;6(6):1375-84. Epub 2011 May 5. PubMed PMID: 21551021;

20. Eckman MH, Kaiser TE, Sherman KE. The Cost-effectiveness of Screening for Chronic Hepatitis B Infection in the United States. Clin Infect Dis. 2011 Jun;52(11):1294-306. Epub 2011 May 2. PubMed PMID: 21540206.

21. Jowett S, Bryan S, Mant J, et al. Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation. Stroke. 2011 Jun;42(6):1717-21. Epub 2011 Apr 21. PubMed PMID: 21512184.

22. Schneider K, Puthanakit T, Kerr S, et al. Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in resource-limited settings. AIDS. 2011 Jun 1;25(9):1143-51. PubMed PMID: 21505319.

23. Cowie MR, Cure S, Bianic F, et al. Cost-effectiveness of highly purified omega-3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting. Eur J Heart Fail. 2011 Jun;13(6):681-9. Epub 2011 Apr 6. PubMed PMID: 21474462.

24. Norman K, Pirlich M, Smoliner C, et al. Cost-effectiveness of a 3-month intervention with oral nutritional supplements in disease-related malnutrition: a randomised controlled pilot study. Eur J Clin Nutr. 2011 Jun;65(6):735-42. Epub 2011 Mar 16. PubMed PMID: 21407248.

25. Courville XF, Hecht PJ, Tosteson AN. Is Total Ankle Arthroplasty A Cost-effective Alternative to Ankle Fusion? Clin Orthop Relat Res. 2011 Jun;469(6):1721-7. Epub 2011 Mar 11. PubMed PMID: 21394559.

26. Biggs SA, Duarte RV, Raphael JH, et al. Influence of a latent period in QALY anaylsis: Pilot study of intrathecal drug delivery systems for chronic non-malignant pain. Br J Neurosurg. 2011 Jun;25(3):401-6. Epub 2011 Feb 28. PubMed PMID: 21355772.

27. Jones AE, Troyer JL, Kline JA. Cost-effectiveness of an emergency department-based early sepsis resuscitation protocol. Crit Care Med. 2011 Jun;39(6):1306-12. PubMed PMID: 21336115; PubMed Central PMCID: PMC3102146.

28. Kondo M, Hoshi SL, Yamanaka T, et al. Economic evaluation of the 21-gene signature (Oncotype DX(®)) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03). Breast Cancer Res Treat. 2011 Jun;127(3):739-49. Epub 2010 Nov 17.  PubMed PMID: 21082239.

29. Majumdar SR, Lier DA, Rowe BH, et al. Cost-effectiveness of a multifaceted intervention to improve quality of osteoporosis care after wrist fracture. Osteoporos Int. 2011 Jun;22(6):1799-808. Epub 2010 Sep 29. PubMed PMID: 20878389.

30. Maniadakis N, Ekman M, Fragoulakis V, et al. Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece. Eur J Health Econ. 2011 Jun;12(3):253-61. Epub 2010 Apr 22. PubMed PMID: 20411401.

By James D. Chambers

By CEA Registry Team on 6/1/2011 8:25 AM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials. The CEA registry includes every cost-utility study published and indexed in Medline (through July 2010).

1. van den Akker ME, Arts MP, van den Hout WB, et al. Tubular diskectomy versus conventional microdiskectomy for the treatment of lumbar disk related sciatica: cost utility analysis alongside a double-blinded randomized controlled trial. Neurosurgery. 2011 May 26. [Epub ahead of print] PubMed PMID: 21623248.

2. Kanis JA, Cooper C, Hiligsmann M, et al. Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int. 2011 May 27. [Epub ahead of print] PubMed PMID: 21617992.

3. Kasteng F, Eriksson J, Sennfält K, et al. Metabolic effects and cost-effectiveness in aripiprazole versus olanzapine in schizophrenia and bipolar disorder. Acta Psychiatr Scand. 2011 May 24. [Epub ahead of print] PubMed PMID: 21609324.

4. Boehler CE, Milton KE, Bull FC, et al. The cost of changing physical activity behaviour: evidence from a "physical activity pathway" in the primary care setting. BMC Public Health. 2011 May 23;11(1):370. [Epub ahead of print] PubMed PMID: 21605400.

5. Carles M, Vilaprinyo E, Cots F, et al. Cost-effectiveness of early detection of breast cancer in Catalonia (Spain). BMC Cancer. 2011 May 23;11(1):192. [Epub ahead of print] PubMed PMID: 21605383.

6. Azuara-Blanco A, Burr JM, Cochran C, et al, Eagle Study Group EI. The effectiveness of early lens extraction with intraocular lens implantation for the treatment of primary angle-closure glaucoma (EAGLE): study protocol for a randomized controlled trial. Trials. 2011 May 23;12(1):133.  [Epub ahead of print] PubMed PMID: 21605352.

7. Hohwü L, Borre M, Ehlers L, Venborg Pedersen K. A short-term cost-effectiveness study comparing robot-assisted laparoscopic and open retropubic radical prostatectomy. J Med Econ. 2011 May 23. [Epub ahead of print] PubMed PMID: 21604962.

8. Arlandis-Guzman S, Errando-Smet C, Trocio J, et al.  Cost-effectiveness analysis of antimuscarinics in the treatment of patients with Overactive Bladder in Spain: A decision-tree model. BMC Urol. 2011 May 20;11(1):9. [Epub ahead of print] PubMed PMID: 21599928.

9. Garau M, Shah KK, Mason AR, Wang et al. Using QALYs in Cancer: A Review of the Methodological Limitations. Pharmacoeconomics. 2011 May 23. [Epub ahead of print] PubMed PMID: 21599035.

10. Havrilesky LJ, Pokrzywinski R, Revicki D, et al. Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer. Cancer. 2011 May 19. [Epub ahead of print] PubMed PMID: 21598242.

11. Muntinghe FL, Vegter S, Verduijn M, et al. Using a genetic, observational study as a strategy to estimate the potential cost-effectiveness of pharmacological CCR5 blockade in dialysis patients. Pharmacogenet Genomics. 2011 May 18. [Epub ahead of print] PubMed PMID: 21597398.

12. Lopes GD. Societal Costs and Benefits of Treatment with Trastuzumab in Patients with Early HER2neu-Overexpressing Breast Cancer in Singapore. BMC Cancer. 2011 May 18;11(1):178. [Epub ahead of print] PubMed PMID: 21586176.
 

By James D. Chambers

By CEA Registry Team on 5/16/2011 7:12 AM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials. The CEA registry includes every cost-utility study published and indexed in Medline (through July 2010).

1. Priest VL, Scuffham PA, Hachamovitch R, et al. Cost-effectiveness of coronary computed tomography and cardiac stress imaging in the emergency department a decision analytic model comparing diagnostic strategies for chest pain in patients at low risk of acute coronary syndromes. JACC Cardiovasc Imaging. 2011 May;4(5):549-56. PMID: 21565744.

2. Beaudet A, Palmer JL, Timlin L, et al.  Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK. J Med Econ. 2011 May 12. [Epub ahead of print] PMID: 21563878.

3. Linas BP, Wong AY, Freedberg KA, et al. Priorities for Screening and Treatment of Latent Tuberculosis Infection in the United States. Am J Respir Crit Care Med. 2011 May 11. [Epub ahead of print] PMID: 21562129.

4. Taylor M, Leonardi-Bee J, Agboola S, et al. Cost Effectiveness of Interventions to Reduce Relapse to Smoking Following Smoking Cessation. Addiction. 2011 May 11. PMID: 21561499.

5. Goto S, Komaba H, Moriwaki K, et al. Clinical Efficacy and Cost-Effectiveness of Lanthanum Carbonate as Second-Line Therapy in Hemodialysis Patients in Japan. Clin J Am Soc Nephrol. 2011 May 5. [Epub ahead of print] PubMed PMID: 21551021.

6. Simpson KN, Dietz B, Baran R, et al. Economic Modeling of the Combined Effects of HIV-Disease, Cholesterol and Lipoatrophy Based on ACTG 5142 Trial Data. Cost Eff Resour Alloc. 2011 May 8;9(1):5. PMID: 21548986.

7. Eckman MH, Kaiser TE, Sherman KE. The Cost-effectiveness of Screening forChronic Hepatitis B Infection in the United States. Clin Infect Dis. 2011 May 6. [Epub ahead of print] PubMed PMID: 21540206.

8. Yang KY, Caughey AB, Little SE, et al. A cost-effectiveness analysis of prophylactic surgery versus gynecologic surveillance for women from hereditary non-polyposis colorectal cancer (HNPCC) Families. Fam Cancer. 2011 May 3. [Epub ahead of print] PubMed PMID: 21538078.

9. Gillespie P, O'Shea E, Murphy AW, et al; for the SPHERE study team. Relative cost effectiveness of the SPHERE intervention in selected patient subgroups with existing coronary heart disease. Eur J Health Econ. 2011 May 3. [Epub ahead of print] PubMed PMID: 21537952.

10. Boriani G, Mantovani LG, Biffi M, et al. Cardiac resynchronization therapy: a cost or an investment? Europace. 2011 May;13 Suppl 2:ii32-8. PubMed PMID: 21518747.

11. Hall PS, Hulme C, McCabe C, et al. Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer: A UK Perspective Considering Duration of Benefit, 12. Long-Term Toxicity and Pattern of Recurrence. Pharmacoeconomics. 2011 May 1;29(5):415-32. PMID: 21504241.

13. Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective. Thromb Haemost. 2011 May 3;105(5):908-19. PMID: 21431243.

14. Chang SL, Cipriano LE, Harshman LC, et al. Cost-effectiveness analysis of nephron sparing options for the management of small renal masses. J Urol. 2011  May;185(5):1591-7. PMID: 21419445.

15. Whitehurst DG, Bryan S, Hay EM, et al. Cost-effectiveness of acupuncture care as an adjunct to exercise-based physical therapy for osteoarthritis of the knee. Phys Ther. 2011 May;91(5):630-41. PMID: 21415230.

16. Lee BY, Stalter RM, Bacon KM, et al. Cost-effectiveness of adjuvanted versus nonadjuvanted influenza vaccine in adult hemodialysis patients. Am J Kidney Dis. 2011 May;57(5):724-32. PMID: 21396760.

17. Dedhia RC, Smith KJ, Johnson JT, et al. The cost-effectiveness of community-based screening for oral cancer in high-risk males in the United States: A Markov decision analysis approach. Laryngoscope. 2011 May;121(5):952-60. PMID: 21384383.

18. Armstrong EP, Malone DC, McCarberg B, et al. Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia. Curr Med Res Opin. 2011 May;27(5):939-50. PMID: 21375358.

19. Harris A, Cooper BA, Li JJ, et al. Cost-effectiveness of initiating dialysis early: a randomized controlled trial. Am J Kidney Dis. 2011 May;57(5):707-15. PMID: 21349618.

20. Lee WC, Conner C, Hammer M. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US. Curr Med Res Opin. 2011 May;27(5):897-906. PMID: 21348806.

21. Kimman ML, Dirksen CD, Voogd AC, et al. Economic evaluation of four follow-up strategies after curative treatment for breast cancer: Results of an RCT. Eur J Cancer. 2011 May;47(8):1175-85. PMID: 21257305.

22. Soini EJ, Martikainen JA, Nousiainen T. Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up. Ann Oncol. 2011 May;22(5):1189-97. PMID: 21135053

23. Wang TS, Cheung K, Roman SA, et al. To supplement or not to supplement: a cost-utility analysis of calcium and vitamin d repletion in patients after thyroidectomy. Ann Surg Oncol. 2011 May;18(5):1293-9. PMID: 21088914.

24. Nagy B, Brennan A, Brandtmüller A, Thomas SK, Sullivan SD, Akehurst R. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models. Int J Geriatr Psychiatry. 2011 May;26(5):483-94. PMID: 20845395.

25. Hartwell D, Jones J, Loveman E, et al. Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation. Cancer Treat Rev. 2011 May;37(3):242-9. Review. PMID: 20709456.

26. Davis JC, Marra CA, Robertson MC, et al. Economic evaluation of dose-response resistance training in older women: a cost-effectiveness and cost-utility analysis. Osteoporos Int. 2011 May;22(5):1355-66. PMID: 20683707.

27. Yaghoubi M, Aghayan HR, Arjmand B, et al. Cost-effectiveness of homograft heart valve replacement surgery: an introductory study. Cell Tissue Bank. 2011 May;12(2):153-8. PMID: 19949875.

By James D. Chambers

By CEA Registry Team on 5/3/2011 8:53 AM

Today (May 3rd) is World Asthma Day, an annual event organized by the Global Initiative for Asthma.   

Asthma is a hugely prevalent and burdensome disease; there are approximately 34 million asthma suffers in the US alone. [1]
 
To recognize the event, we would like to take the opportunity to highlight some of the literature in the CEA Registry that studies this disease and its treatments.  
 
We searched for ‘Asthma’ within the CEA Registry and identified 27 articles and 79 unique cost-effectiveness ratios.  We limited the list to what we considered “high quality” studies (meaning that our readers gave it a score of at least 4.5 on a scale from 1 (low) to 7 (high).  
 
As illustrated in table 1, recently published high-quality studies examining asthma treatments and diagnostics encompass a wide-range of incremental value, from cost-saving and health improving, to nearly $300,000 per QALY ($US2010).  Click on the Article ID to find out more about each study.
 

Table 1. Recently published high quality (>4.5) cost-utility studies for asthma treatments 

Article ID

Author, Journal,
Pub. Year

Intervention

Comparator

Population

ICER

2010-01-06325

Wilson, ECF,
Pharmaco-economics,
2010

Leukotriene receptor antagonist as an add-on therapy for asthma (montelukast 10mg 1x daily)

Long acting beta-2 agonist as an add-on therapy for asthma

UK patients aged 12 – 80 treated in primary care settings and receiving inhaled corticosteroids for asthma treatment and who, in the opinion of their primary care physician, were in need of an increase in therapy. Societal Perspective

$46,000

2010-01-06085

Campbell, JD,
Allergy,
2010

Omalizumab plus usual care, inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA)

Usual care, inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA)

US patients with moderate-to-severe persistent asthma, a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroid (ICS)

$290,000

2009-01-05260

Price, D,
Allergy,
2009

Asthma management using a fractional exhaled nitric oxide hand-held monitor (NIOX MINO)

Standard diagnostic tests

United Kingdom patients with mild to severe asthma

Dominates

2008-01-04479

Brüggenjürgen, B et al,
Ann Allergy Asthma Immunol,
2008

Subcutaneous immunotherapy (SCIT) with symptomatic treatment (ST) 

Symptomatic treatment (ST) only

Allergic rhinitis and allergic asthma in the German population including children, adolescents, and adults; societal perspective

Dominates

2008-01-04336

Nasser, S et al,
Allergy,
2008

Grazax treatment for 3 years beginning 4 months before grass pollen 

Usual care: placebo group – taking symptomatic medication alone

Patients with rhinoconjunctivitis and co-existing asthma

                                            

$8,800

 
The CEA Registry includes all original cost-utility analysis published in peer reviewed English-language health and medical journals up to July 2010 (updates are regular0.  Currently, >2,500 cost-utility analyses are included in the database, corresponding to >6,700 unique cost-effectiveness ratios and >9,000 utility weights.
 
By: Michael J. Cangelosi and James D. Chambers
 
Reference
[1]: American Lung Association. Epidemiology and Statistics Unit, Research and Program Services. Trends in Asthma Morbidity and Mortality, November 2007.  Accessed via: American Academy of Allergy, Asthma and Immunology.  Asthma Statistics.  Available here
 
 
By CEA Registry Team on 5/2/2011 8:25 AM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials. The CEA registry includes every cost-utility study published and indexed in Medline (through July 2010).

1. Fujiike K, Mizuno Y, Hiratsuka Y, et al; The Strabismus Surgery Study Group. Quality of life and cost-utility assessment after strabismus surgery in adults. Jpn J Ophthalmol. 2011 Apr 27. [Epub ahead of print] PubMed PMID: 21523376.

2. Roberts TE, Tsourapas A, Middleton LJ, et al. Hysterectomy, endometrial ablation, and levonorgestrel releasing intrauterine system (Mirena) for treatment of heavy menstrual bleeding: cost effectiveness analysis. BMJ. 2011 Apr 26;342:d2202. PMID: 21521730.

3. Barton GR, Goodall M, Bower P, et al. Increasing heart-health lifestyles in deprived communities: economic evaluation of lay health trainers. J Eval Clin Pract. 2011 Apr 24. PubMed PMID: 21518152.

4. Jowett S, Bryan S, Mant J, et al. Cost Effectiveness of Warfarin Versus Aspirin in Patients Older Than 75 Years With Atrial Fibrillation. Stroke. 2011 Apr 21. [Epub ahead of print] PubMed PMID: 21512184.

5. Long EF, Owens DK. The cost-effectiveness of a modestly effective HIV vaccine in the United States. Vaccine. 2011 Apr 18. [Epub ahead of print] PubMed PMID: 21510996.

6. Chuang LH, Soares MO, Watson JM, et al; on behalf of the VenUS III team. Economic evaluation of a randomized controlled trial of ultrasound therapy for hard-to-heal venous leg ulcers. Br J Surg. 2011 Apr 20. [Epub ahead of print]PubMed PMID: 21509750.

7. Morris S, Morris TP, McGregor AH, et al. Function after spinal treatment, exercise and rehabilitation (FASTER): cost-effectiveness analysis based on a randomised controlled trial. Spine (Phila Pa 1976). 2011 Apr 19. [Epub ahead of print] PubMed PMID: 21505377.

8. Schneider K, Puthanakit T, Kerr S, et al. Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in resource-limited settings. AIDS. 2011 Apr 18. [Epub ahead of print] PubMed PMID: 21505319.

9. Michaelidis CI, Zimmerman RK, Nowalk MP, et al. Estimating the cost-effectiveness of a national program to eliminate disparities in influenza vaccination rates among elderly minority groups. Vaccine. 2011 Apr 27;29(19):3525-30. Epub 2011 Mar 12. PubMed PMID: 21406266.

By James D. Chambers

By CEA Registry Team on 4/17/2011 2:07 PM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials. The CEA registry includes every cost-utility study published and indexed in Medline (through July 2010).

 
1. Gelsomino S, Lorusso R, Livi U, et al. Cost and cost-effectiveness of cardiac surgery in elderly patients. J Thorac Cardiovasc Surg. 2011 Apr 12. [Epub ahead of print] PubMed PMID: 21492881.
 
2. Thijssen AS, Broeders IA, de Wit GA, et al. Cost-effectiveness of proton pump inhibitors versus laparoscopic Nissen fundoplication for patients with gastroesophageal reflux disease: a systematic review of the literature. Surg Endosc. 2011 Apr 13. [Epub ahead of print] PubMed PMID: 21487859.
 
3. Dewilde S, Brüggenjürgen B, Nienaber C, et al. Cost-effectiveness of adjunctive eptifibatide in patients undergoing coronary stenting in Germany. Eur J Health Econ. 2011 Apr 12. [Epub ahead of print] PubMed PMID: 21484498.
 
4. Suter LG, Fraenkel L, Braithwaite RS. Cost-effectiveness of Adding Magnetic Resonance Imaging to Rheumatoid Arthritis Management. Arch Intern Med. 2011 Apr 11;171(7):657-67. PubMed PMID: 21482840.
 
5. Scotland G, McLernon D, Kurinczuk J, et al. Minimising twins in in vitro fertilisation: a modelling study assessing the costs, consequences and cost-utility of elective single versus double embryo transfer over a 20-year time horizon. BJOG. 2011 Apr 8. [Epub ahead of print] PubMed PMID:21477172.
 
6. Neovius K, Buesch K, Sandström K, et al. Cost-Effectiveness Analysis of Palivizumab as RSV-Prophylaxis in Preterm Infants in Sweden. Acta Paediatr. 2011 Apr 7. [Epub ahead of print] PubMed PMID: 21477089.
 
7. Cowie MR, Cure S, Bianic F, et al. Cost-effectiveness of highly purified omega-3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting. Eur J Heart Fail. 2011 Apr 6. [Epub ahead of print] PubMed PMID: 21474462.
 
8. Hartwell D, Jones J, Baxter L, et al. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess. 2011 Apr;15(17):1-210. PubMed PMID: 21473834.
 
9. Carter JA, Joshi A, Kaura S, et al. Cost effectiveness of zoledronic acid in the management of skeletal metastases in hormone-refractory prostate cancer patients in France, Germany, Portugal, and the Netherlands. J Med Econ. 2011 Apr 6. [Epub ahead of print] PubMed PMID: 21469915.
 
10. Pinto AM, Kuppermann M, Nakagawa S, et al. Comparison and correlates of three preference-based health-related quality-of-life measures among overweight and obese women with urinary incontinence. Qual Life Res. 2011 Apr 3. [Epub ahead of print] PubMed PMID:21461953.
 
11. Ara R, Pandor A, Stevens J, et al. Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy? Eur J Cardiovasc Prev Rehabil. 2011 Apr 1. [Epub ahead of print] PubMed PMID: 21460076.
 
12. Sigvant B, Henriksson M, Lundin F, et al. Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective? Eur J Cardiovasc Prev Rehabil. 2011 Apr;18(2):254-61. Epub 2011 Jan 28. PubMed PMID: 21450673.
 
13. Patel A, Maissi E, Chang HC, et al. Motivational enhancement therapy with and without cognitive behaviour therapy for Type 1 diabetes: economic evaluation from a randomized controlled trial. Diabet Med. 2011 Apr;28(4):470-9. PubMed PMID: 21392068.
 
14. Padula WV, Mishra MK, Makic MB, et al. Improving the quality of pressure ulcer care with prevention: a cost-effectiveness analysis. Med Care. 2011 Apr;49(4):385-92. PubMed PMID: 21368685.
 
15. Koleva D, De Compadri P, Padula A, et al. Economic evaluation of human papilloma virus vaccination in the European Union: a critical review. Intern Emerg Med. 2011 Apr;6(2):163-74. Epub 2011 Feb 11. PubMed PMID: 21312004.
 
16. Purmonen TT, Pänkäläinen E, Turunen JH, et al. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncol. 2011 Apr;50(3):344-52. Epub 2011 Feb 8. PubMed PMID: 21299447.
 
17. Lier D, Ross S, Tang S, et al. Trans-obturator tape compared with tension-free vaginal tape in the surgical treatment of stress urinary incontinence: a cost utility analysis. BJOG. 2011 Apr;118(5):550-556. 
Epub 2011 Feb 4. PubMed PMID: 21291510.
 
18. Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Curr Med Res Opin. 2011 Apr;27(4):713-30. Epub 2011 Jan 25. PubMed PMID: 21265593.
 
19. Thuresson PO, Heeg B, Lescrauwaet B, et al.  Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden. Scand J Infect Dis. 2011 Apr;43(4):304-12. Epub 2011 Jan 13. PubMed PMID: 21231811.
 
20. Klersy C, De Silvestri A, Gabutti G, et al. Economic impact of remote patient monitoring: an integrated economic model derived from a meta-analysis of randomized controlled trials in heart failure. Eur J Heart Fail. 2011 Apr;13(4):450-9. Epub 2010 Dec 29. PubMed PMID: 21193439.
 
21. Malmivaara K, Kivisaari R, Hernesniemi J, et al. Cost-effectiveness of
decompressive craniectomy in traumatic brain injuries. Eur J Neurol. 2011
Apr;18(4):656-62. Epub 2010 Dec 22. PubMed PMID: 21175999.
 
22. Anis AH, Bansback N, Sizto S, et al. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. J Dermatolog Treat. 2011 Apr;22(2):65-74. Epub 2010 May 5. PubMed PMID: 20443663.
 
By James D. Chambers
By CEA Registry Team on 4/2/2011 10:28 AM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials. The CEA registry includes every cost-utility study published and indexed in Medline (through July 2010).

1. Greving J, Visseren F, de Wit G, et al. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. BMJ.  2011 Mar 30;342:d1672. PubMed PMID: 21450800.

2. Miller SM, Goldstein JL, Gerson LB. Cost-Effectiveness Model of Endoscopic Biopsy for Eosinophilic Esophagitis in Patients With Refractory GERD. Am J Gastroenterol. 2011 Mar 29. [Epub ahead of print] PubMed PMID: 21448144.

3. Longworth L, Sculpher MJ, Bojke L, Tosh JC. Bridging the gap between methods research and the needs of policy makers: A review of the research priorities of the National Institute for Health and Clinical Excellence. Int J Technol Assess Health Care. 2011 Mar 29:1-8. [Epub ahead of print] PubMed PMID: 21447260.

4. Goossens LM, Nivens MC, Sachs P, et al. Is the EQ-5D responsive to recovery from a moderate COPD exacerbation? Respir Med. 2011 Mar 23. [Epub ahead of print] PubMed PMID: 21439807.

5. Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective. Thromb Haemost. 2011 Mar 22;105(5). [Epub ahead of print] PubMed PMID: 21431243.

6. Le QA, Doctor JN. Probabilistic Mapping of Descriptive Health Status Responses Onto Health State Utilities Using Bayesian Networks: An Empirical Analysis Converting SF-12 Into EQ-5D Utility Index in a National US Sample. Med Care. 2011 Mar 18. [Epub ahead of print] PubMed PMID: 21422961.

7. Chang SL, Cipriano LE, Harshman LC, et al. Cost-Effectiveness Analysis of Nephron Sparing Options for the Management of Small Renal Masses. J Urol. 2011 Mar 16. [Epub ahead of print] PubMed PMID: 21419445.

8. Whitehurst DG, Bryan S, Hay EM, et al. Cost-Effectiveness of Acupuncture Care as an Adjunct to Exercise-Based Physical Therapy for Osteoarthritis of the Knee. Phys Ther. 2011 Mar 17. [Epub ahead of print] PubMed PMID: 21415230.

9. Norman K, Pirlich M, Smoliner C, et al. Cost-effectiveness of a 3-month intervention with oral nutritional supplements in disease-related malnutrition: a randomised controlled pilot study. Eur J Clin Nutr. 2011 Mar 16. [Epub ahead of print] PubMed PMID: 21407248.

10. Hodis HN, Mack WJ. A "window of opportunity:" The reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent. Brain Res. 2011 Mar 16;1379:244-52. PubMed PMID: 20977895

By James D. Chambers
 

By CEA Registry Team on 3/15/2011 1:59 PM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials. The CEA registry includes every cost-utility study published and indexed in Medline (through July 2010).

1. Lee BY, Stalter RM, Bacon KM, et al. Cost-Effectiveness of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Adult Hemodialysis Patients. Am J Kidney Dis. 2011 Mar 9. [Epub ahead of print] PubMed PMID: 21396760.

2. Sicuri E, Muñoz J, Pinazo MJ, et al. Economic evaluation of Chagas disease screening of pregnant Latin American women and of their infants in a non endemic area. Acta Trop. 2011 Mar 8. [Epub ahead of print] PubMed PMID: 21396345.

3. Courville XF, Hecht PJ, Tosteson AN. Is Total Ankle Arthroplasty A Cost-effective Alternative to Ankle Fusion? Clin Orthop Relat Res. 2011 Mar 11. [Epub ahead of print] PubMed PMID: 21394559.

4. Smith DH, Raebel MA, Chan KA, et al. An economic evaluation of a laboratory monitoring program for Renin-Angiotensin system agents. Med Decis Making. 2011 Mar-Apr;31(2):315-24. PubMed PMID: 21393563.

5. Alistar SS, Owens DK, Brandeau ML. Effectiveness and Cost Effectiveness of Expanding Harm Reduction and Antiretroviral Therapy in a Mixed HIV Epidemic: A Modeling Analysis for Ukraine. PLoS Med. 2011 Mar;8(3):e1000423. Epub 2011 Mar 1. PubMed PMID: 21390264.

6. Dedhia RC, Smith KJ, Johnson JT, Roberts M. The cost-effectiveness of community-based screening for oral cancer in high-risk males in the United States: A Markov decision analysis approach. Laryngoscope. 2011 Mar 7. [Epub ahead of print] PubMed PMID: 21384383.

7. Lynch FL, Dickerson JF, Clarke G, et al. Incremental Cost-effectiveness of Combined Therapy vs Medication Only for Youth With Selective Serotonin Reuptake Inhibitor-Resistant Depression: Treatment of SSRI-Resistant Depression in Adolescents Trial Findings. Arch Gen Psychiatry. 2011 Mar;68(3):253-62. PubMed PMID: 21383263.

8. Knight C, Mauskopf J, Ekelund M, et al. Cost-effectiveness of treatment with etanercept for psoriasis in Sweden. Eur J Health Econ. 2011 Mar 6. [Epub ahead of print] PubMed PMID: 21380772.

9. Garrett S, Elley CR, Rose SB, et al. Are physical activity interventions in primary care and the community cost-effective? A systematic review of the evidence. Br J Gen Pract. 2011 Mar;61(584):125-33. PubMed PMID: 21375895

10. Armstrong EP, Malone DC, McCarberg B, et al. Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia. Curr Med Res Opin. 2011 Mar 4. [Epub ahead  of print] PubMed PMID: 21375358.

11. Schipper LG, Kievit W, den Broeder AA, et al. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective. Rheumatology (Oxford). 2011 Mar 2. [Epub ahead of print] PubMed PMID: 21371999.

12. Padula WV, Mishra MK, Makic MB, et al. Improving the Quality of Pressure Ulcer Care With Prevention: A Cost-Effectiveness Analysis. Med Care. 2011 Mar 1. [Epub ahead of print] PubMed PMID: 21368685.

13. Mahoney EM, Greenberg D, Lavelle TA, et al DJ. Costs and cost-effectiveness of carotid stenting versus endarterectomy for patients at increased surgical risk: Results from the SAPPHIRE trial. Catheter Cardiovasc Interv. 2011 Mar 1;77(4):463-72. PubMed PMID: 21351220.

14. Brändle M, Azoulay M, Greiner RA. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland. Int J Clin  Pharmacol Ther. 2011 Mar;49(3):217-30. PubMed PMID: 21329624.

15. Grosso AM, Bodalia PN, Macallister RJ, et al. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis. Int J Clin Pract. 2011 Mar;65(3):253-63. Epub 2011 Feb 1. PubMed PMID: 21284790.

16. Greeley SA, John PM, Winn AN, et al. The Cost-Effectiveness of Personalized Genetic Medicine: The case of genetic testing in neonatal diabetes. Diabetes Care. 2011 Mar;34(3):622-7. Epub 2011 Jan 27. PubMed PMID: 21273495

17. Osnes-Ringen H, Kvamme M, Kristiansen I, et al. Cost-effectiveness analyses of elective orthopaedic surgical procedures in patients with inflammatory arthropathies. Scand J Rheumatol. 2011 Mar;40(2):108-15. Epub 2011 Jan 17. PubMed PMID: 21241197.

18. Reed SD, Scales CD Jr, etal. Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer. J Urol. 2011 Mar;185(3):841-7. Epub 2011 Jan 15. PubMed PMID: 21239023.

19. Ament JD, Stryjewski TP, Pujari S, Siddique S, Papaliodis GN, Chodosh J, Dohlman CH. Cost effectiveness of the type II Boston keratoprosthesis. Eye (Lond). 2011 Mar;25(3):342-9. Epub 2010 Dec 24. PubMed PMID: 21183944.

20. van Breugel NH, Bidar E, Essers BA, et al. Cost-effectiveness of ablation surgery in patients with atrial fibrillation undergoing cardiac surgery. Interact Cardiovasc Thorac Surg.  2011 Mar;12(3):394-8. Epub 2010 Dec 10. PubMed PMID: 21148666.

21. Ljungman D, Lundholm K, Hyltander A. Cost-utility estimation of surgical treatment of pancreatic carcinoma aimed at cure. World J Surg. 2011 Mar;35(3):662-70. PubMed PMID: 21132294.

22. Joerger M, Matter-Walstra K, Früh M, et al. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol. 2011 Mar;22(3):567-74. Epub 2010 Sep 13. PubMed PMID: 20843984.

23. Malmivaara K, Ohman J, Kivisaari R, et al. Cost-effectiveness of decompressive craniectomy in non-traumatic neurological emergencies. Eur J Neurol. 2011 Mar;18(3):402-9. PubMed PMID: 20636370.

24. Borgström F, Ström O, Kleman M, et al. Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective. Osteoporos Int. 2011 Mar;22(3):955-65. Epub 2010 Jun 8. PubMed PMID: 20532482.

By James D. Chambers

By CEA Registry Team on 2/16/2011 3:21 PM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials. The CEA registry includes every cost-utility study published and indexed in Medline (through July 2010).

1: Koleva D, De Compadri P, Padula A, et al. Economic evaluation of human papilloma virus vaccination in the European Union: a critical review. Intern Emerg Med. 2011 Feb 11. [Epub ahead of print] PMID: 21312004.

2: Haller M, Gutjahr G, Kramar R, et al. Cost-effectiveness analysis of renal replacement therapy in Austria. Nephrol Dial Transplant. 2011 Feb 10. [Epub ahead of print] PubMed PMID: 21310740.

3: Choudhry NK, Patrick AR, Glynn RJ, et al. The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels. J Am Coll Cardiol. 2011 Feb 15;57(7):784-91. PubMed PMID:21310313.

4: Purmonen TT, P Nk L Inen E, Turunen JH, Asseburg et al. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncol. 2011 Feb 8. [Epub ahead of print] PMID: 21299447.

5: Waters RC, Ostermann J, Reeves TD, et al. A cost-effectiveness analysis of alternative HIV re-testing strategies in sub-Saharan Africa. J Acquir Immune Defic Syndr. 2011 Feb 4. [Epub ahead of print] PMID: 21297484.

6: Jeroen L, Christiaan M, Niel H, et al. Imputing QALYs from Single Time Point Health State Descriptions on the EQ-5D and the SF-6D:  A Comparison of Methods for Hepatitis A Patients. Value Health. 2011 Feb 4. [Epub ahead of print] PMID: 21296602.

7: Lal LS, Byfield SD, Chang EL, et al. Cost-effectiveness Analysis of a Randomized Study Comparing Radiosurgery With Radiosurgery and Whole Brain Radiation Therapy in Patients With 1 to 3 Brain Metastases. Am J Clin Oncol. 2011 Feb 2. [Epub ahead of print] PMID: 21293245.

8: Dretzke J, Edlin R, Round J, et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease. Health Technol Assess. 2011 Feb;15(6):1-250. PMID: 21291629.

9: Lier D, Ross S, Tang S, Robert M, Jacobs P; for the Calgary Women’s Pelvic Health Research Group. Trans-obturator tape compared with tension-free vaginal tape in the surgical treatment of stress urinary incontinence: a cost utility analysis. BJOG. 2011 Feb 4. [Epub ahead of print] PMID: 21291510.

10: Broder MS, Chang EY, Bentley TG, et al. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naive human immunodeficiency virus-infected patients in the United States. J Med Econ. 2011 Feb 2. [Epub ahead of print] PMID: 21288058.

11: Grosso AM, Bodalia PN, Macallister RJ, et al. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis. Int J Clin Pract. 2011 Mar;65(3):253-63. PMID: 21284790.

12: You JH. Pharmacoeconomic evaluation of warfarin pharmacogenomics. Expert Opin Pharmacother. 2011 Feb;12(3):435-41. PMID: 21231897.

13: Klersy C, De Silvestri A, Gabutti G, et al. Economic impact of remote patient monitoring: an integrated economic model derived from a meta-analysis of randomized controlled trials in heart failure. Eur J Heart Fail. 2011 Feb 1. [Epub ahead of print] PMID: 21193439.

14: Grima DT, Airia P, Attard C, Hutchison CA. Modelled cost-effectiveness of high cut-off haemodialysis compared to standard haemodialysis in the management of myeloma kidney. Curr Med Res Opin. 2011 Feb;27(2):383-91. PMID: 21175375.

15: Yiee JH, Baskin LS. Use of internal stent, external transanastomotic stent or no stent during pediatric pyeloplasty: a decision tree cost-effectiveness analysis. J Urol. 2011 Feb;185(2):673-80. PMID:21172705.

16: Svatek RS, Lotan Y. Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen. Cancer Prev Res (Phila). 2011 Feb;4(2):277-83. PMID: 21163937.

17: Prosser LA, Meltzer MI, Fiore A et al. Effects of Adverse Events on the Projected Population Benefits and Cost-effectiveness of Using Live Attenuated Influenza Vaccine in Children Aged 6 Months to 4 Years. Arch Pediatr Adolesc Med. 2011 Feb;165(2):112-8. PMID: 20921341.

18: Whitehead SJ, Forest-Bendien VL, Richard JL, et al. Economic evaluation of Vacuum Assisted Closure® Therapy for the treatment of diabetic foot ulcers in France. Int Wound J. 2011 Feb;8(1):22-32. PMID: 20875048.

19: Wang YC, Cheung AM, Bibbins-Domingo K, et al. Effectiveness and cost-effectiveness of blood pressure screening in adolescents in the United States. J Pediatr. 2011 Feb;158(2):257-64.e1-7. PMID: 20850759.

20: Landfeldt E, Lundkvist J, Ström O. The societal burden of poor persistence to treatment of osteoporosis in Sweden. Bone. 2011 Feb 1;48(2):380-8. PMID: 20850576.

21: Davidson T, Ekermo B, Gaines H, et al. The cost-effectiveness of introducing nucleic acid testing to test for hepatitis B, hepatitis C, and human immunodeficiency virus among blood donors in Sweden. Transfusion. 2011 Feb;51(2):421-9. PMID: 20849409.

22: Round JA, Jacklin P, Fraser RB, et al. Screening for gestational diabetes mellitus: cost-utility of different screening strategies based on a woman's individual risk of disease. Diabetologia. 2011 Feb;54(2):256-63. PMID: 20809381.

23: Valentine WJ, Aagren M, Haglund M, et al. Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in  Sweden. Scand J Public Health. 2011 Feb;39(1):79-87. PMID: 20688795.

24: Grann VR, Patel PR, Jacobson JS, et al. Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. Breast Cancer Res Treat. 2011 Feb;125(3):837-47. PubMed PMID: 20644999.

By James D. Chambers

By CEA Registry Team on 2/1/2011 6:40 PM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials. The CEA registry includes every cost-utility study published and indexed in Medline (through April 2010).

1. Meyer M, Nance JW Jr, Schoepf UJ et al. Cost-effectiveness of substituting dual-energy CT for SPECT in the assessment of myocardial perfusion for the workup of coronary artery disease. Eur J Radiol. 2011 Jan 27. [Epub ahead of print]
PMID: 21277132

2. Greeley SA, John PM, Winn AN, et al. The Cost-Effectiveness of Personalized Genetic Medicine: The case of genetic testing in neonatal diabetes. Diabetes Care. 2011 Jan 27. [Epub ahead of print] PMID: 21273495

3. Nguyen-Huynh MN, Johnston SC. Is Mechanical Clot Removal or Disruption a Cost-Effective Treatment for Acute Stroke? AJNR Am J Neuroradiol. 2011 Jan 27. [Epub ahead of print] PMID: 21273349

4. Uegaki K, Stomp-van den Berg SG, de Bruijne MC, et al. Cost-utility analysis of a one-time supervisor telephone contact at 6-weeks post-partum to prevent extended sick leave following maternity leave in The Netherlands: results of an economic evaluation alongside a randomized controlled trial. BMC Public Health. 2011 Jan 27;11(1):57. [Epub ahead of print] PMID: 21272325

5. Skidmore G, Ackerman SJ, Bergin C, et al. Cost-effectiveness of the X-STOP® Interspinous Spacer for lumbar spinal stenosis: a comparison with conservative care and laminectomy. Spine (Phila Pa 1976). 2011 Jan 25. [Epub ahead of print]
PMID: 21270713

6. Antoñanzas F, Brenes F, Molero JM, et al. Cost-Effectiveness of the Combination Therapy of Dutasteride and Tamsulosin in the Treatment of Benign Prostatic Hyperlasia in Spain. Actas Urol Esp. 2011 Jan 24. [Epub ahead of print] PMID: 21269736

7. Benedict A, Figlin RA, Sandström P, et al. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. BJU Int. 2011 Jan 25. [Epub ahead of print] PMID: 21265994

8. Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Curr Med Res Opin. 2011 Jan 25. [Epub ahead of print] PMID: 21265593

9. Kimman ML, Dirksen CD, Voogd AC, et al. Economic evaluation of four follow-up strategies after curative treatment for breast cancer: Results of an RCT.
Eur J Cancer. 2011 Jan 21. [Epub ahead of print] PMID: 21257305

10. Shan DE, Wu HC, Chan LY, et al. Cost-Utility Analysis of Parkinson's Disease. Acta Neurol Taiwan. 2011 Jan 18. [Epub ahead of print] PMID: 21249581

11. Zanocco K, Heller M, Sturgeon C. Cost-effectiveness of parathyroidectomy for primary hyperparathyroidism. Endocr Pract. 2011 Jan 17:1-14. [Epub ahead of print] PMID: 21247844

12. Edwards SJ, Wordsworth S, Clarke MJ. Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam. Eur J Health Econ. 2011 Jan 18. [Epub ahead of print] PMID: 21243514

13. Osnes-Ringen H, Kvamme M, Kristiansen I, et al. Cost-effectiveness analyses of elective orthopaedic surgical procedures in patients with inflammatory arthropathies. Scand J Rheumatol. 2011 Jan 17. [Epub ahead of print] PMID: 21241197

14. Luan FL, Kommareddi M, Ojo AO. Universal Prophylaxis is Cost Effective in Cytomegalovirus Serology-Positive Kidney Transplant Patients. Transplantation. 2011 Jan 27;91(2):237-44.

By James D. Chambers

By CEA Registry Team on 1/21/2011 9:50 AM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials. The CEA registry includes every cost-utility study published and indexed in Medline (through April 2010).

1. Reed SD, Scales CD Jr, Stewart SB, et al. Effects of Family History and Genetic Polymorphism on the Cost-Effectiveness of Chemoprevention With Finasteride for Prostate Cancer.  J Urol. 2011 Jan 14. [Epub ahead of print] PMID: 21239023 [PubMed - as supplied by publisher]Related citations

2. Roth JA, Carlson JJ. Cost-Effectiveness of Gemcitabine + Cisplatin vs. Gemcitabine Monotherapy in Advanced Biliary Tract Cancer. J Gastrointest Cancer. 2011 Jan 15. [Epub ahead of print] PMID: 21234709

3. You JH. Pharmacoeconomic evaluation of warfarin pharmacogenomics. Expert Opin Pharmacother. 2011 Jan 14. [Epub ahead of print] PMID: 21231897

4. Thuresson PO, Heeg B, Lescrauwaet B, et al.  Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden.  Scand J Infect Dis. 2011 Jan 13. [Epub ahead of print] PMID: 21231811

5. Corrieri S, Heider D, Riedel-Heller SG, et al.  Cost-effectiveness of fall prevention programs based on home visits for seniors aged over 65 years: a systematic review. Int Psychogeriatr. 2011 Jan 12:1-13. [Epub ahead of print] PMID: 21223626

6.  Akehurst R, Brereton N, Ariely R, et al.  The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands. J Med Econ. 2011;14(1):53-64. Epub 2011 Jan 11. PMID: 21222506

7. Schwenkglenks M, Brazier JE, Szucs TD, et al.  Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes. Value Health. 2011 Jan;14(1):24-33.PMID: 21211483

8. Cummins E, Asseburg C, Punekar YS, et al.  Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis.  Value Health. 2011 Jan;14(1):15-23.PMID: 21211482

9.  Pollock RF, Valentine WJ, Pilgaard T, et al.  The cost effectiveness of rapid-acting insulin aspart compared with human insulin in type 2 diabetes patients: an analysis from the Japanese third-party payer perspective.  J Med Econ. 2011;14(1):36-46. PMID: 21192769

10.  Bós AM, Howard BV, Beresford SA, et al.  Cost-effectiveness analysis of a low-fat diet in the prevention of breast and ovarian cancer. J Am Diet Assoc. 2011 Jan;111(1):56-66.PMID: 21185966 [PubMed - indexed for MEDLINE]Related citations

11. Tsai AG.  A quality-adjusted life year of prevention: the cost-effectiveness of nutrition counseling. J Am Diet Assoc. 2011 Jan;111(1):53-5. PMID: 21185965

12. van Asselt AD, Nicolaï SP, Joore MA, et al; on behalf of the Exercise Therapy in Peripheral Arterial Disease (EXITPAD) study Group. Cost-effectiveness of Exercise Therapy in Patients with Intermittent Claudication: Supervised Exercise Therapy versus a 'Go Home and Walk' Advice. Eur J Vasc Endovasc Surg. 2011 Jan;41(1):97-103 PMID: 21159527

13. Dale W, Bilir SP, Hemmerich J, et al.  The prevalence, correlates, and impact of logically inconsistent preferences in utility assessments for joint health states in prostate cancer. Med Care. 2011 Jan;49(1):59-66. PMID: 21150801

14.  Affleck AG, Bottomley JM, Auland M, et al.  Cost effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of scalp psoriasis in Scotland.  Curr Med Res Opin. 2011 Jan;27(1):269-84. PMID: 21142836

15. Perez MV, Kumarasamy NA, Owens DK, et al.  Cost-Effectiveness of Genetic Testing in Family Members of Patients With Long-QT Syndrome. Circ Cardiovasc Qual Outcomes. 2011 Jan 1;4(1):76-84. PMID: 21139095

16. Higgins KM. What treatment for early-stage glottic carcinoma among adult patients: CO2 endolaryngeal laser excision versus standard fractionated external beam radiation is superior in terms of cost utility? Laryngoscope. 2011 Jan;121(1):116-34.PMID: 21120828

17. Meng Y, Ward S, Cooper K, et al. Cost-effectiveness of MRI and PET imaging for the evaluation of axillary lymph node metastases in early stage breast cancer. Eur J Surg Oncol. 2011 Jan;37(1):40-6. PMID: 21115232

18. Dinh TA, Rosner BI, Atwood JC, et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila). 2011 Jan;4(1):9-22 PMID: 21088223

19. Siddiqui MR, Gay N, Edmunds WJ, et al. Economic evaluation of infant and adolescent hepatitis B vaccination in the UK. Vaccine. 2011 Jan 10;29(3):466-75. PMID: 21073988

20. Walensky RP, Wood R, Fofana MO, et al; Cost-Effectiveness of Preventing AIDS Complications-International Investigators. The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa. J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):26-35.PMID: 21068674

21. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011 Jan 4;154(1):1-11. PMID: 21041570

22. Soini EJ, García San Andrés B, Joensuu T. Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information. Ann Oncol. 2011 Jan;22(1):215-23. PMID: 20627875

23. Jeyarajah S, Adams KJ, Higgins L, et al. Prospective evaluation of a colorectal cancer nurse follow-up clinic. Colorectal Dis. 2011 Jan;13(1):31-8. PMID: 19674021
 

By CEA Registry Team on 1/3/2011 10:32 AM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials. The CEA registry includes every cost-utility study published and indexed in Medline (through April 2010).

1. Ament JD, Stryjewski TP, Pujari S, et al. Cost effectiveness of the type II Boston keratoprosthesis. Eye (Lond). 2010 Dec 24. [Epub ahead of print] PMID: 21183944

2. Moeremans K, Hemmett L, Hjelmgren J, et al. Cost Effectiveness of Darunavir/Ritonavir 600/100 mg bid in Treatment-Experienced, Lopinavir-Naive, Protease Inhibitor-Resistant, HIV-Infected Adults in Belgium, Italy, Sweden and the UK. Pharmacoeconomics. 2010 Dec 23;28(S1):147-167 PMID: 21182349

3. Brogan A, Mauskopf J, Talbird SE, et al. US Cost Effectiveness of Darunavir/Ritonavir 600/100 mg bid in Treatment-Experienced, HIV-Infected Adults with Evidence of Protease Inhibitor Resistance Included in the TITAN Trial. Pharmacoeconomics. 2010 Dec 23;28(S1):129-146.  PMID: 21182348

4. Moeremans K, Annemans L, Löthgren M, et al. Cost Effectiveness of Darunavir/Ritonavir 600/100 mg bid in Protease Inhibitor-Experienced, HIV-1-Infected Adults in Belgium, Italy, Sweden and the UK. Pharmacoeconomics. 2010 Dec 23;28(S1):107-128. PMID: 21182347

5. Mauskopf J, Brogan A, Martin S, et al. Cost Effectiveness of Darunavir/Ritonavir in Highly Treatment-Experienced, HIV-1-Infected Adults in the USA. Pharmacoeconomics. 2010 Dec 23;28(S1):83-105 PMID: 21182346

6. Malmivaara K, Kivisaari R, Hernesniemi J, et al. Cost-effectiveness of decompressive craniectomy in traumatic brain injuries. Eur J Neurol. 2010 Dec 22. [Epub ahead of print] PMID: 21175999

7. Grima DT, Airia P, Attard C, et al. Modelled cost-effectiveness of high cut-off haemodialysis compared to standard haemodialysis in the management of myeloma kidney. Curr Med Res Opin. 2010 Dec 23. [Epub ahead of print]PMID: 21175375

8. Long EF, Brandeau ML, Owens DK. The Cost-Effectiveness and Population Outcomes of Expanded HIV Screening and Antiretroviral Treatment in the United States. Ann Intern Med. 2010 Dec 21;153(12):778-89. PMID: 21173412

9. Yiee JH, Baskin LS. Use of Internal Stent, External Transanastomotic Stent or No Stent During Pediatric Pyeloplasty: A Decision Tree Cost-Effectiveness Analysis. J Urol. 2010 Dec 18. [Epub ahead of print] PMID: 21172705

10. Luan FL, Kommareddi M, Ojo AO. Universal Prophylaxis is Cost Effective in Cytomegalovirus Serology-Positive Kidney Transplant Patients. Transplantation. 2010 Dec 16. [Epub ahead of print] PMID: 21169881

11. Leong RK, de Wachter SG, Joore MA, et al. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder. BJU Int. 2010 Dec 16. [Epub ahead of print] PMID: 21166750

12. Lenoir-Wijnkoop I, van Aalderen WM, Boehm G, et al. Cost-effectiveness model for a specific mixture of prebiotics in The Netherlands. Eur J Health Econ. 2010 Dec 17. [Epub ahead of print] PMID: 21165666

13. Blumberg EA, Hauser IA, Stanisic S, et al. Prolonged prophylaxis with valganciclovir is cost effective in reducing posttransplant cytomegalovirus disease within the United States. Transplantation. 2010 Dec 27;90(12):1420-6. PMID: 21063245

By James D. Chambers

By CEA Registry Team on 12/15/2010 3:15 PM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials. The CEA registry includes every cost-utility study published and indexed in Medline (through April 2010).

1. van Breugel NH, Bidar E, Essers BA, et al. Cost-effectiveness of ablation surgery in patients with atrial fibrillation undergoing cardiac surgery. Interact Cardiovasc Thorac Surg. 2010 Dec 10. [Epub ahead of print] PMID: 21148666

2. Affleck AG, Bottomley JM, Auland M, et al. Cost effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of scalp psoriasis in Scotland. Curr Med Res Opin. 2010 Dec 13. [Epub ahead of print] PMID: 21142836

3. Tamayama K, Hoshi SL, Kondo M, et al. Cost-effectiveness Analysis of Pre-seasonal Medication for Cedar Pollinosis in Japan. Yakugaku Zasshi. 2010 Dec;130(12):1725-36.PMID: 21139400

4. Perez MV, Kumarasamy NA, Owens DK, et al. Cost-Effectiveness of Genetic Testing in Family Members of Patients With Long-QT Syndrome. Circ Cardiovasc Qual Outcomes. 2010 Dec 7. [Epub ahead of print] PMID: 21139095

5. Soini EJ, Martikainen JA, Nousiainen T. Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up. Ann Oncol. 2010 Dec 6. [Epub ahead of print] PMID: 21135053

6. Ljungman D, Lundholm K, Hyltander A. Cost-Utility Estimation of Surgical Treatment of Pancreatic Carcinoma Aimed at Cure. World J Surg. 2010 Dec 4. [Epub ahead of print] PMID: 21132294

7. Lindholt JS. Abdominal aortic aneurysms. Dan Med Bull. 2010 Dec;57(12):B4219. PMID: 21122465 [PubMed - in process]

8. Troyer JL, McAuley WJ, McCutcheon ME. Cost-effectiveness of medical nutrition therapy and therapeutically designed meals for older adults with cardiovascular disease. J Am Diet Assoc. 2010 Dec;110(12):1840-51. PMID: 21111094

9. Chow IH, Tang CH, You SL, et al. Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system. Br J Cancer. 2010 Dec 7;103(12):1773-82. PMID: 21102588

10. Contreras-Hernandez I, Becker D, Chancellor J, et al. Cost-Effectiveness of Maraviroc for Antiretroviral Treatment-Experienced HIV-infected Individuals in Mexico. Value Health. 2010 Dec;13(8):903-914. PMID: 21091827

11. van Eerd MC, Mario Ouwens JN, de Peuter MA. Cost-effectiveness study comparing pharmaceutically licensed plasma for transfusion (OctaplasLG®) versus fresh frozen plasma (FFP) in critically Ill patients in the UK. Transfus Apher Sci. 2010 Dec;43(3):251-9. PMID: 21084224

12. Gerlier L, Lamotte M, Wille M, et al. The cost utility of autologous chondrocytes implantation using ChondroCelect® in symptomatic knee cartilage lesions in Belgium. Pharmacoeconomics. 2010 Dec 1;28(12):1129-46.  PMID: 21080737 [PubMed - in process]

13. Mavranezouli I. A review and critique of studies reporting utility values for schizophrenia-related health states. Pharmacoeconomics. 2010 Dec 1;28(12):1109-21. PMID: 21080736

14. Jit M, Cromer D, Baguelin M, et al. The cost-effectiveness of vaccinating pregnant women against seasonal influenza in England and Wales. Vaccine. 2010 Dec 10;29(1):115-22. PMID: 21055501

15. Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis.  Lancet Infect Dis. 2010 Dec;10(12):845-52. PMID: 21051295

16. Werner EJ. Preoperative hemostatic screening for pediatric adenotonsillar surgery: worthwhile effort or waste of resources? Pediatr Blood Cancer. 2010 Dec 1;55(6):1045-6. PMID: 20979166

17. Clement FM, Klarenbach S, Tonelli M, et al. An economic evaluation of erythropoiesis-stimulating agents in CKD. Am J Kidney Dis. 2010 Dec;56(6):1050-61.  PMID: 20932621

18. Gohel MS, Epstein DM, Davies AH. Cost-effectiveness of traditional and endovenous treatments for varicose veins. Br J Surg. 2010 Dec;97(12):1815-23 PMID: 20922783

19. Spangler EL, Dillavou ED, Smith KJ. Cost-effectiveness of guidelines for insertion of inferior vena cava filters in high-risk trauma patients. J Vasc Surg. 2010 Dec;52(6):1537-1545.e2. Epub 2010 Sep 16.PMID: 20843631

20. Dakin H, Bentley A, Dusheiko G.  Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Value Health. 2010 Dec;13(8):922-33. PMID: 20825619

21. Cooper JD, Smith KJ, Ritchey AK. A cost-effectiveness analysis of coagulation testing prior to tonsillectomy and adenoidectomy in children. Pediatr Blood Cancer. 2010 Dec 1;55(6):1153-9.PMID: 20672369

22. Traill WB, Shankar B, Brambila-Macias J, et al. Interventions to promote healthy eating habits: evaluation and recommendations. Obes Rev. 2010 Dec;11(12):895-8. PMID: 20202134

By James D. Chambers
 

By CEA Registry Team on 12/1/2010 10:58 AM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials. The CEA registry includes every cost-utility study published and indexed in Medline (through April 2010).

 

1. Meng Y, Ward S, Cooper K, et al.  Cost-effectiveness of MRI and PET imaging for the evaluation of axillary lymph node metastases in early stage breast cancer.  Eur J Surg Oncol. 2010 Nov 27. [Epub ahead of print] PMID: 21115232

2. Linde C, Mealing S, Hawkins N, et al; on behalf of the REVERSE study group. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction).  Eur Heart J. 2010 Nov 25. [Epub ahead of print]PMID: 21112898

3. Kim N, Yang B, Lee T, et al. An economic analysis of usual care and acupuncture collaborative treatment on chronic low back pain: A Markov model decision analysis. BMC Complement Altern Med. 2010 Nov 25;10(1):74. [Epub ahead of print] PMID: 21106108

4.  Davis JC, Robertson MC, Comans T, et al.  Guidelines for conducting and reporting economic evaluation of fall prevention strategies. Osteoporos Int. 2010 Nov 23. [Epub ahead of print] PMID: 21104231

5. Chow IH, Tang CH, You SL, et al.  Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system. Br J Cancer. 2010 Nov 23. [Epub ahead of print] PMID: 21102588

6. Contreras-Hernandez I, Becker D, Chancellor J, Kühne F, et al.  Cost-Effectiveness of Maraviroc for Antiretroviral Treatment-Experienced HIV-infected Individuals in Mexico. Value Health. 2010 Nov 22. doi: 10.1111/j.1524-4733.2010.00798.x. [Epub ahead of print] PMID: 21091827

7. Agarwal A, Kumar DA.  Cost-effectiveness of cataract surgery.  Curr Opin Ophthalmol. 2010 Nov 23. [Epub ahead of print] PMID: 21088579

8. Wang TS, Cheung K, Roman SA, et al.  To Supplement or Not to Supplement: A Cost-Utility Analysis of Calcium and Vitamin D Repletion in Patients After Thyroidectomy. Ann Surg Oncol. 2010 Nov 19. [Epub ahead of print] PMID: 21088914

9. Dinh TA, Rosner BI, Atwood JC, et al.  Health Benefits and Cost-Effectiveness of Primary Genetic Screening for Lynch Syndrome in the General Population.  Cancer Prev Res (Phila). 2010 Nov 18. [Epub ahead of print] PMID: 21088223

10. Kozminski MA, Neumann PJ, Nadler ES, et al.  How Long and How Well: Oncologists' Attitudes Toward the Relative Value of Life-Prolonging v. Quality of Life-Enhancing Treatments.  Med Decis Making. 2010 Nov 18. [Epub ahead of print] PMID: 21088130

11. Smart KA, Paes BA, Lanctôt KL.  Changing costs and the impact on RSV prophylaxis.  J Med Econ. 2010 Nov 18. [Epub ahead of print] PMID: 21087075

12.  Zaniolo O, Iannazzo S, Pradelli L, et al.  Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy.  Eur J Health Econ. 2010 Nov 18. [Epub ahead of print] PMID: 21086017

13. van Eerd MC, Mario Ouwens JN, de Peuter MA.  Cost-effectiveness study comparing pharmaceutically licensed plasma for transfusion (OctaplasLG®) versus fresh frozen plasma (FFP) in critically Ill patients in the UK.  Transfus Apher Sci. 2010 Dec;43(3):251-9. Epub 2010 Nov 16.PMID: 21084224

14. Baeten SA, van Exel NJ, Dirks M, et al.  Lifetime health effects and medical costs of integrated stroke services - a non-randomized controlled cluster-trial based life table approach.  Cost Eff Resour Alloc. 2010 Nov 17;8(1):21. [Epub ahead of print] PMID: 21083901

15.  Kondo M, Hoshi SL, Yamanaka T, et al.  Economic evaluation of the 21-gene signature (Oncotype DX(®)) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03).  Breast Cancer Res Treat. 2010 Nov 17. [Epub ahead of print] PMID: 21082239

16.  Talbird SE, Taylor TN, Knoll S, et al.  Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries.  Vaccine. 2010 Nov 19;28 Suppl 6:G23-9. PMID: 21075266
 

By James D. Chambers

 

By CEA Registry Team on 11/18/2010 10:50 AM

Here at the CEA Registry, some readers have asked about our process for identifying and selecting articles to include in the Registry and about how we extract information from the published papers. This blog post will address those queries.

 

Each month, a CEA Registry researcher executes a Medline search, using keywords “quality-adjusted”, “QALY”, and “cost-utility”. Typically, this search will identify over 100 articles. Two CEA Registry researchers then review the abstracts from these articles and flag those that appear to present an original economic evaluation with results reported as incremental costs per QALY accrued – removing methods papers, review articles, non-cost utility articles, and analyses that use a non-QALY metric for health benefits (e.g. life-years or DALYs). Approximately 75% of the articles identified in our original search are eliminated at this step. Finally, researchers retrieve copies of articles for any abstract identified for inclusion by either researcher. 
 
Two CEA Registry reviewers from our pool of reviewers then independently review and extract salient information from each obtained article using standardized abstraction formsEach reviewer records data on methods and results reported in the article (i.e. ICER ratios and utility weights), and then meet to reach a consensus on any discrepancies between their independently collected data. If after discussing the article they agree it describes an original cost per QALY economic analysis, the data is sent back to CEA Registry researchers for final editing. 
 
Researchers within the CEA Registry review the data collected and ensure that the intent of the reviewer is clearly communicated in the data. Finally, the data is entered into the Tufts CEA Registry with the consensus information about its methods, ratios, and utility weights for distribution to the world.
 
by: Michael J Cangelosi

 

By CEA Registry Team on 11/16/2010 8:15 AM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials. The CEA registry includes every cost-utility study published and indexed in Medline (through April 2010).

By CEA Registry Team on 11/1/2010 10:49 AM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials. The CEA registry includes every cost-utility study published and indexed in Medline (through April 2010).

By CEA Registry Team on 10/26/2010 9:07 AM

The most recent issue of Health Economics gives us an opportunity to highlight the diversity of interventions addressed by studies catalogued in the CEA Registry.  A study in that issue by Sperber et al. evaluates a law banning cell phone use by drivers in the Canadian province of Alberta.  The study concluded that a ban would both improve health and save money.(1) This study will be included in the CEA Registry in due course.

The CEA registry includes all cost-utility analyses (CUAs) indexed in Medline, including many that address interventions outside the domain of medicine.  After reading cost-effectiveness analysis on cell phones and driving, I searched the registry for other CUAs related to car safety.  Below is a brief summary of selected studies.

By CEA Registry Team on 10/18/2010 3:10 PM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials. The CEA registry includes every cost-utility study published and indexed in Medline (through April 2010).

By CEA Registry Team on 10/1/2010 10:59 AM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials. The CEA registry (www.cearegistry.org) includes every cost-utility study published and indexed in Medline.

By CEA Registry Team on 9/1/2010 2:14 PM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials. The CEA registry (www.cearegistry.org) includes every cost-utility study published and indexed in Medline.

By CEA Registry Team on 8/17/2010 5:50 PM

Each month we highlight recently published cost utility studies and selected reviews and editorials. The CEA registry (www.cearegistry.org)  includes every cost-utility study published and indexed in Medline.

By CEA Registry Team on 7/15/2010 11:37 AM

Each month we highlight recently published cost utility studies and selected reviews and editorials. For the purpose of this blog we focus on those journals that most frequently publish cost-effectiveness/cost-utility studies. Please note that the CEA registry (www.cearegistry.org) includes every cost-utility study published and indexed in Medline.

By CEA Registry Team on 6/16/2010 9:55 AM

Each month we highlight recently published cost utility studies and selected reviews and editorials. For the purpose of this blog we focus on those journals that most frequently publish cost-effectiveness/cost-utility studies. Please note that the CEA registry (www.cearegistry.org) includes every cost-utility study published and indexed in Medline.

By CEA Registry Team on 5/17/2010 5:57 PM

Each month we highlight recently published cost utility studies and selected reviews and editorials. For the purpose of this blog we focus on those journals that most frequently publish cost-effectiveness/cost-utility studies. Please note that the CEA registry (www.cearegistry.org) includes every cost-utility study published and indexed in Medline.

By CEA Registry Team on 4/15/2010 8:32 AM

Each month we highlight recently published cost utility studies and selected reviews and editorials. For the purpose of this blog we focus on those journals that most frequently publish cost-effectiveness/cost-utility studies. Please note that the CEA registry (www.cearegistry.org) includes every cost-utility study published and indexed in Medline

By CEA Registry Team on 4/8/2010 5:48 PM

When reviewing an economic evaluation one aspect that is traditionally thought to be important is the source of funding. Indeed, funding status is a variable collected in the Tufts Medical Center Cost-Effectiveness Analysis (CEA) Registry (www.cearegistry.org).

Please view the blog archive for earlier entries

Search This Blog